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S U M M  A H I
The aim of this study was to investigate the effects of field 
stimulation and drugs on neurotransmission in the vas deferens.
Field stimulation of mouse isolated vasa resulted in biphasic 
motor responses that were abolished by tetrodotoxin (TTX). The 
initial component of this response was selectively inhibited by 
morphine and clonidine. The second component was inhibited by 
phentolamine.
After 6-hydroxydopamine (6-OHDA) pretreatment, field stimulation 
produced a small, monophasic contraction, which was unaffected by 
phentolamine and by TTX. Vasa from 6-OHDA pretreated mice were 
supersensitive to noradrenaline (NA).
In control anaesthetised rats, motor responses of the in situ 
vas to field stimulation or to spinal nerve stimulation were 
biphasic and were abolished by TTX. After 6-OHDA pretreatment, 
in situ field stimulation produced monophasic contractions 
that were resistant to TTX, suggesting that these responses may 
be non-neuronal, resulting from direct stimulation of super­
sensitive smooth muscle.
Morphine and clonidine potentiated the second noradrenergic 
component of the biphasic motor response to field stimulation 
at a time when the overflow of radioactivity from vasa 
preincubated with (^H)-NA was increased.
The ability of morphine and clonidine to potentiate the field 
stimulation-induced overflow of radioactivity occurred in the 
presence of a combination of drugs which block the removal 
mechanisms for NA.
vi
7) NA and electrical field stimulation increased phosphoinositide 
hydrolysis, reflected in [^^P]-phosphatidic acid (PA) formation 
in the mouse vas deferens and these responses were blocked by 
prazosin and by TTX.
8) Neither morphine nor clonidine affected basal levels of 
[3^P]-PA formation or the ability of NA to enhance [^2P]-PA 
formation but both drugs potentiated the ability of field 
stimulation to increase the formation of [32P]-PA. This 
suggests that these drugs enhance the field stimulation-induced 
release of NA in the mouse vas deferens. A possible 
explanation for the findings that morphine and clonidine 
apparently inhibit release of one co-transmitter whilst 
potentiating the release of another is discussed.
9) Part of the study investigated the effects of chronically 
treating mice with thyroxine (T^). The level of T^ in the 
serum was increased in mice pretreated with T^, and this was 
accompanied by changes in pre- and post-synaptic receptor 
sensitivity.
10) Pretreatment with T^ produced a presynaptic subsensitivity to 
morphine and clonidine and a postsynaptic subsensitivity to 
NA and carbachol. In these animals, the ability of morphine 
and clonidine to potentiate the overflow of (^H)-NA was 
diminished. A possible explanation for these observations 
is considered.
I N T R O D U C T I O N
1The existence of what is now known as the autonomic nervous system 
has been recognised for several centuries. The term ’sympathetic' 
applied to the peripheral nerves was introduced in 1732 by the Danish 
anatomist Winslow (Bowman & Rand, 1981), who believed that this system 
of nerves was responsible for regulating the 'sympathies' or 
interrelationships of organs in the body. The modern concept of the 
autonomic nervous system is based to a large extent on the anatomical 
and physiological studies of Gaskell and Langley. Gaskell (1886) 
demonstrated the functional connection through the white rami 
communicantes between the central nervous system and the sympathetic 
chains, and the connections of the grey rami to spinal nerves. He 
also recognised that the prevertebral ganglia were part of the 
sympathetic division. Gaskell grouped the cranial, sacral and 
thoracolumbar outflows from the spinal cord together with the 
sympathetic trunks and the prevertebral and other ganglia as the 
'involuntary nervous system' (1916). Langley (1898) first proposed 
the designation 'autonomic nervous system', which included both the 
sympathetic and parasympathetic divisions, and this term has now been 
generally adopted.
NEUROCHEMICAL TRANSMISSION
The development of the concept that the nervous impulse is 
transmitted across synapses and neuroeffector junctions by a chemical 
mediator arose largely from studies of autonomic nervous function 
(Elliott, 1904; Loewi, 1921). Initially, there were two theories of 
transmission: the electrical theory and the humoral theory (Du Bois
Reymond, 1877; Kuhne, 1888; Elliott, 1904; Loewi, 1921; Cannon & 
Bacq, 1931). The electrical theory held that transmission was brought 
about by the spread of nerve action currents to the tissue. However, 
the nerve impulse must in some way achieve amplification in order to
2excite the larger muscle mass. The humoral theory, which proposes 
that chemicals with specific actions are released from nerves, provides 
a more satisfactory explanation for amplification of impulses. This 
theory also provides an explanation for the observation that both 
excitation and inhibition can be produced in one tissue by stimulation 
of both sympathetic and parasympathetic nerves (Loewi, 1921).
Throughout the history of physiology, drugs have had an important 
role in analysing the operation of biological systems (Bernard, 1856; 
Langley, 1905; Dale, 1914). The effects of drugs have been examined 
in poorly understood systems, providing useful information about drug 
action and biological function. Had physiologists relied solely on 
the use of drugs whose mechanisms of action were fully understood, it 
is likely that little advance in our knowledge would have been made.
The development of the theory of chemical transmission and the 
evidence implicating acetylcholine (ACh) and noradrenaline (NA) as the 
chemical mediators of the autonomic nervous system has been reviewed 
(Gershon, 1970). A remarkable similarity between the effects produced 
by muscarine and the effects of peripheral nerve stimulation had been 
observed, and the blocking action of atropine noted (Dixon, 1907;
Dixon & Brodie, 1903)• However, it was later established that ACh 
rather than muscarine was likely to be the parasympathetic transmitter 
substance (Dale, 1914).
A similar pattern had been noted in the action of suprarenal 
extracts, sympathetic nerve stimulation and administration of 
adrenaline (Langley, 1901; Elliott, 1904). On stimulation of nerves 
at the lower end of the sympathetic chain in adrenalectomised animals, 
a substance passed into the blood producing the effects of sympathetic 
stimulation on other organs (Cannon & Bacq, 1931). This transmitter 
of sympathetic effects was referred to as 'sympathin* and was suggested 
to be either adrenaline or a very closely-related substance (Bacq,
31933). However, the effects of the transmitter carried by the blood 
from sympathetic nerve endings and the effects of injected adrenaline 
were not identical. This observation led to the theory that during 
sympathetic nerve stimulation, adrenaline is indeed released, but acts 
solely as a mediator, combining with an excitatory or an inhibitory 
substance localised in the receptors to form two complexes which would 
be the active substances (Cannon & Rosenbleuth, 1933)* This theory 
received little support, and evidence was later presented that 
noradrenaline (NA) is the predominant catecholamine released on 
stimulation of the sympathetic nerves. There was no evidence that it 
was modified in any way before reaching the effector cells (Von Euler, 
1946). Several studies have now confirmed and extended these 
observations, and all the evidence indicates that in mammals, the main 
transmitters liberated on stimulation of the post-ganglionic 
sympathetic and parasympathetic nerves are, respectively, NA and ACh.
POSTSYNAPTIC RECEPTORS
In the physiology of nerve transmission, the idea of a specialised 
tissue element on which the nerve impulse acted, which intervened 
between nerve and muscle and which was the site of action of such 
poisons as curare, long preceded the theory of chemical neuro­
transmission (Bernard, 1857)* On the basis of a famous experiment in 
which Bernard showed that nicotine applied to a particular part of the 
surface of a muscle elicited twitching and that this effect was 
prevented by curare, Langley (1905) postulated the existence of a 
•receptive substance' located on the muscle rather than on the nerve 
endings. He suggested that this 'receptive substance’ existed in more 
than one form in autonomic effector cells.
At an early stage it was realised that ACh had two main types of 
action which could be reproduced by the drugs muscarine and nicotine.
4Muscarinic receptors are present in heart, smooth muscle and salivary 
glands, and are excited by muscarine and allied synthetic substances 
and blocked by atropine and atropine-like drugs. Nicotinic receptors, 
present in skeletal muscle, parasympathetic and sympathetic ganglia and 
the adrenal medulla, are activated by many substances structurally- 
related to nicotine but are blocked by high concentrations of nicotine 
(Dale, 1914). When the muscarinic receptors are blocked by atropine, 
the effects of ACh acting on nicotinic receptors in sympathetic 
ganglion cells are uncovered (Dale, 1914). It was postulated, 
therefore, that there were two types of receptor for ACh, and these 
were designated muscarinic and nicotinic. The distinction between the 
two types of cholinoceptor isoreceptors was clarified because of the 
historical accident that many of the potent alkaloids that attracted 
the attention of early pharmacologists acted specifically on either 
muscarinic or nicotinic sites. Relatively few studies on isoreceptors 
of cholinoceptors have been carried out. However, there have been 
several studies on isoreceptors of adrenoceptors, starting with 
Ahlquist's differentiation in 1948 between a- and (3-adrenoceptors and 
extended by Furchgott in 1972, based on the relative potencies of 
various adrenergic agonists and on the susceptibility of blockade by 
specific drugs. However, it was not until the introduction of 
specific P-adrenoceptor antagonist drugs that the classification of a- 
and P-adrenoceptors was accepted (Powell & Slater, 1958). Thereafter, 
P-adrenoceptors were further subdivided into P^- and P2- 
adrenoceptors on the basis of the differential sensitivity of various 
tissues to a series of P-adrenoceptor agonists and antagonists (Lands, 
1967).
5PRESYNAPTIC RECEPTORS
In the peripheral nervous system, the magnitude of a tissue’s 
response to nerve stimulation is related to the rate of transmitter 
release and this in turn is controlled by the frequency of impulse 
traffic, which is centrally determined (Brazier, 1960). However, from 
evidence accumulated over the last 3 decades, it is clear that 
transmitter release can also be controlled peripherally. Various 
observations suggest that neurally-released, hormonal and locally- 
formed substances, such as the prostaglandins, can influence 
transmitter release (see reviews, Starke, 1977; Westfall, 1977).
This form of peripheral control appears to be mediated by receptors 
located on nerve varicosities - the sites of transmitter release from 
nerves. However, for a long time it was generally accepted that nerve 
endings specialised in the production, storage and release of chemical 
transmitter but were devoid of receptors, which were thought to be 
confined to the postsynaptic membranes of the cells upon which the 
neurotransmitters acted (Dale, 1952). Contrary observations had been 
intermittently reported but had received little attention. In tracing 
the development of pharmacology, examples can be found where advances 
in understanding were followed by periods of tunnel vision. For 
example, theories such as electrical neurotransmission (Kuhne, 1888) 
and, later, autonomic nerves releasing only ACh or NA, took years to be 
supplanted by new ideas. Eventually the weight of evidence refuting a 
long-accepted principle renders a change in our view inevitable. 
However, recent years have seen a remarkable change. Nerve terminals 
have been found to be invested with a multitude of receptor-types 
(Stjarne, 1975bj Langer, 1977; Starke, 1977; 1981).
Much of the evidence which has established the hypothesis of local 
regulation of transmitter release has been derived from experiments in 
which the effects of agonist and antagonist drugs have been examined on
6the overflow of transmitter released by nerve stimulation. The 
overflow of transmitter is the amount that escapes recapture by nerves 
(Uptake^), extraneuronal cells (Uptake2) or enzymatic inactivation, and 
is recovered in organ perfusates or tissue bathing fluid.
The first demonstration that drugs could increase sympathetic 
transmitter overflow was provided by Brown and Gillespie (1956, 1957) 
using the perfused cat spleen, which is a suitable organ for overflow 
studies because of its 'open type' of circulation. The amount of NA 
appearing in the venous blood following adrenergic nerve stimulation 
was related to the frequency of splenic nerve stimulation, with a 
maximum overflow at a frequency of 30 Hz (Brown & Gillespie, 1957).
The overflow of transmitter was not altered by inhibitors of monoamine 
oxidase (MAO) (Brown & Gillespie, 1957; Brown et al.f 1959) which, at 
that time, was thought to be the main enzyme responsible for the 
inactivation of NA. In the cholinergic system, it was known that ACh 
was destroyed by a cholinesterase, and this somewhat simpler mechanism 
of transmitter removal had been projected to the adrenergic system in 
order to simplify it. However, when the oe-adrenoceptor antagonists 
dibenamine and phenoxybenzamine (PBA) were added to the blood-perfused 
spleen, there was a large increase in NA overflow, which was greater 
with stimulation at a frequency of 10 Hz than at 30 Hz. Knowing that 
both drugs blocked a-adrenoceptors, Brown and Gillespie concluded that 
NA released by nerve endings was taken up by receptor sites in the 
smooth muscle before being destroyed. When these receptor sites were 
blocked by PBA or dibenamine, most of the released amine overflowed 
into the venous blood.
This conclusion was later challenged by Paton (1960) on the basis 
of similar experiments carried out on the adrenal gland. The nerves 
innervating adrenal medullary cells release ACh which acts on the gland 
to release adrenaline and NA. At this site, as at the nerve endings,
7the amount of amine appearing in the blood leaving the gland was 
dependent on the frequency of stimulation, with very little overflow at 
low frequencies. Brown and Gillespie had attributed this effect at 
nerve endings to a combination of amine with receptors, yet in this 
situation there are no local receptors. Paton offered another 
explanation. He suggested that some of the amine liberated by the 
medullary cell was taken back into the cell between stimuli, and the 
greater amount in the venous blood at high frequencies of stimulation 
followed from the reduction in time available for this uptake. The 
existence of a neuronal uptake mechanism (Uptake^) was soon 
demonstrated and its characteristics established (Iversen, 1967).
Drugs such as PBA were found to have the ability to inhibit Uptake^ 
(Hertting si. aL., 1961; Gillespie, 1966; Iversen, 1967), thereby 
adding weight to Paton’s hypothesis. An extraneuronal uptake process 
(Uptake2) was also characterised (Avakian & Gillespie, 1968; Kalsner 
& Nickerson, 1969). It was suggested that PBA increased transmitter 
release by blocking neuronal uptake (Thoenen si ILL, 1964). However, 
PBA and other a-adrenoceptor antagonists can increase NA overflow in 
concentrations which do not inhibit neuronal or extraneuronal uptake 
(Starke, 1977; Westfall, 1977). Indeed, it is doubtful whether 
blockade of the uptake mechanisms alone can significantly increase NA 
overflow (Kalsner, 1981). In particular, it is paradoxical that in 
the vas deferens, which possesses a dense adrenergic innervation, 
inhibition of the uptake mechanisms with highly selective drugs should 
result in such a small increase in NA overflow (Farnebo & Malmfors, 
1971).
In the early 1970’s, four groups of workers independently proposed 
the hypothesis that NA regulates its own release by activating a- 
adrenoceptors located on the nerve terminal (Farnebo & Hamberger, 1971; 
Kirpekar & Puig, 1971; Langer ££. £l., 1971; Starke, 1971). Several
8lines of evidence supported this view. PBA and other a-adrenoceptor 
antagonists, used in concentrations too low to inhibit neuronal or 
extraneuronal uptake, were found to increase NA overflow (Langer, 1970; 
Starke al., 1971; Cripps & Dearnaley, 1972). Drugs which blocked 
neuronal uptake caused only a small increase in the overflow of NA 
following nerve stimulation. In contrast, a-adrenoceptor antagonists 
produced a much larger increase in transmitter overflow. Haggendal 
(1970) reported that PBA enhanced the amount of NA in the overflow from 
the nerve stimulated tissue even after inhibition of local re-uptake of 
liberated NA.
The idea that presynaptic a-adrenoceptors may regulate the nerve 
stimulation-evoked release of transmitter has been substantiated by 
observations that PBA and phentolamine increase the overflow of 
dopamine-P-hydroxylase, an enzyme present in adrenergic storage 
vesicles. This enzyme is not affected by uptake or degradative 
enzymes, and is released by exocytosis during nerve stimulation along 
with NA. Since dopamine-p-hydroxylase is, therefore, a good marker 
of NA release from nerves, the increased overflow of this granular 
component probably results from an increased release from the amine 
granules in the nerve terminals (Johnson et al.. 1971; De Potter et 
al.. 1971). Further evidence for the existence of a negative feedback 
mechanism was provided by a-adrenoceptor agonists, which inhibit NA 
overflow evoked by nerve stimulation in many tissues including the 
rabbit heart (Starke at al., 1971)» rabbit pulmonary artery (Starke e£ 
al.. 1975)» cat spleen (Kirpekar at al>» 1973)> rabbit ear artery (Rand 
et al.. 1973) and guinea-pig vas deferens (Stjarne, 1974). A 
characteristic feature of the ability of a-adrenoceptor agonists and 
antagonists to affect NA release is their ineffectiveness at high 
frequencies of stimulation (Brown & Gillespe, 1957; Langer, 1977). 
Difficulties arise in attempting to relate the ineffectiveness of
9exogenous a-adrenoceptor agonists and antagonists using such stimulation 
parameters to the presynaptic receptor hypothesis. If the 
concentration of neurally-released NA was sufficiently high to 
fully activate the presynaptic a receptors and exert a maximum 
inhibition, then this could not be further enhanced by exogenous 
agonists (Langer, 1977; Starke, 1977). However, this explanation 
fails to accommodate the observation that a-adrenoceptor antagonists 
have little effect at high frequencies of stimulation. If NA was 
indeed exerting a maximum inhibitory effect then, under such 
circumstances, a-adrenoceptor antagonists would be expected to have 
their greatest effect to potentiate the release of transmitter. Such 
inconsistencies have led to the validity of the presynaptic receptor 
hypothesis being challenged (Kalsner, 1982; 1983a;b; Kalsner &
Quillan, 1984) and an alternative explanation being put forward to 
account for the effects of antagonists on stimulation-evoked efflux of 
transmitter (Kalsner, 1983a). a-Adrenoceptor antagonist-induced 
increases in field stimulation-induced transmitter overflow should 
follow a predictable pattern if due to the interruption of a negative 
feedback system. The increases in overflow should be proportional to 
the level of ongoing feedback in the absence of antagonists and should 
be explicable in terms of the amount of NA present in the synapse to 
activate presynaptic receptors during nerve stimulation. However, in 
a variety of tissues from several species this was not found (Kalsner & 
Quillan, 1984). a-Adrenoceptor antagonists had their most pronounced 
effects to enhance overflow when the concentration of transmitter in 
the synapse was low, contrary to expectations for a negative feedback 
system.
The process of transmitter release from sympathetic nerve 
terminals is believed to be related to the duration of the action 
potential. Prolongation of the stimulation period allows the calcium
10
channels to stay open longer, permitting a greater entry of the ion and 
an increase in the amount of transmitter released. It has been 
proposed that the presynaptic action of a-adrenoceptor antagonists is 
linked to a prolongation of the duration of depolarisation and, 
consequently, is most likely to be seen with short pulse durations 
(Kalsner, 1983a). This possible explanation is substantiated by the 
finding that tetraethylammonium, a selective blocker of outward 
potassium channels (Szurszewski, 1978) known to prolong the duration of 
the action potential, acts to increase transmitter efflux (Kalsner & 
Quillan, 1984).
The development of a variety of new a-adrenoceptor agonists 
provided evidence that, although the inhibitory effect of NA was 
mediated through a-adrenoceptors, these were not identical with the 
familiar postjunctional a-adrenoceptors and differed in their 
sensitivity to drugs (Cambridge si al,- 1977; Doxey al.., 1977)
On the basis of this evidence, adrenoceptors were classified as either 
Oj-(postjunctional) or a2~(prejunctional) subtypes (Langer, 1977; 
Starke, 1977; 1981). It was assumed that the entire population of 
postjunctional a-adrenoceptors was of the a^  subtype. However, a sub­
population of a-adrenoceptors, which were resistant to the selective a- 
adrenoceptor antagonist prazosin was later identified in vascular 
smooth muscle of rat and cat (Bentley et al.f 1977). This was 
supported by a similar finding in human arteries (Moulds & Jauernig, 
1977) and led to the breakdown of the original anatomical 
classification and the emergence of a new pharmacological 
classification of non-neuronal or postjunctional o^-adrenoceptors 
(Docherty afc. al., 1979; Timmermans .§£. al-» 1979). These 
a2-adrenoceptors have been reported in many organ systems, for example, 
platelets, pancreatic islets, adipocytes and kidneys. Thus, autonomic 
neurotransmission is brought about by chemical transmitters which are
11
released in response to nerve impulses. These transmitters interact 
with specific receptors on the postsynaptic effector cell to trigger a 
response, and their release is subject to regulation by receptors 
situated presynaptically on nerve endings.
SENSITIYITT CHAHBES IH AUTONOMIC EFFECTOBS
A characteristic of intrinsic importance for the survival of an 
organism is its ability to adapt to the external environment. These 
adaptations, which are prompted by environmental stimuli, vary in time- 
course, ranging from evolutionary changes which take many years to 
develop, to rapid adaptations required to protect the animal from a 
sudden hostile environment (Gibson, 1981). Many of the rapid 
alterations are initiated by the release of chemical mediators which 
act in concert, providing a physiological means of adapting tissue 
sensitivity to meet the particular requirements of the animal (Guyton, 
1971). Two systems which are of prime importance in maintaining the 
conditions necessary for the continued existence of an organism are the 
autonomic nerves and the endocrine glands (Bernard, 1878; Canon,
1929). Both of these systems are involved in influencing smooth 
muscle sensitivity, which is not fixed, but is subject to change.
Under certain conditions the amount of stimulant required to produce a 
response is less than normal, and this phenomenon is known as super­
sensitivity, 
i) Supersensitivity
Supersensitivity (Cannon & Rosenbleuth, 1949; Trendelenburg,
1972; Fleming <§Jl al., 1973; Thesleff, 1974; Westfall, 1981) 
generally occurs as a result of the removal of a tonic stimulus, and 
early observations of changes in the sensitivity of effector organs 
involved surgical denervation (Budge, 1855). Two types of super­
sensitivity could be demonstrated as a result of denervation of the
12
cat nictitating membrane (Langer & Trendelenburg, 1966; Trendelenburg, 
1966), one of which was specific for NA, the other of which was non­
specific. The specific supersensitivity produced by NA could be 
attributed to the destruction of the adrenergic neurones, which are 
normally sites of loss for exogenously administered NA. A similar 
type of supersensitivity occurs when the block of inactivation is at a 
postjunctional site (Graefe & Trendelenburg, 1974; Trendelenburg & 
Graefe, 1975). This type of supersensitivity has been described as 
'deviation* supersensitivity on account of its occurrence after removal 
of the sites of loss of the agents concerned (Fleming, 1975). As a 
consequence of this loss, the concentration of agonist which reaches 
the receptors of the effector organ increases, resulting in an enhanced 
response.
Non-specific or ’non-deviation' supersensitivity has been 
attributed to an increase in receptor number (Langer & Trendelenburg, 
1968; Bito & Dawson, 1970). Sensitivity changes occur at several 
receptors, and the phenomenon is slow in onset, often occurring several 
days after surgical denervation of a tissue. It is likely that there 
is also a change in the effector cells at a level beyond the agonist- 
receptor interaction, for example, at sites where the excitation of 
several receptors converge on a common biochemical pathway (Hudgins & 
Fleming, 1968; Fleming, 1968).
Supersensitivity of a tissue to a receptor ligand is reflected in 
a leftwards displacement of the dose-response curve for one or more 
agonists (Cannon & Rosenbleuth, 1949). This occurs when the responses 
to all submaximal doses of agonist are increased, but the maximum 
response is unchanged. This is the type of supersensitivity most 
commonly seen in smooth muscle (Fleming £i. al., 1973). However, an 
increase in the maximum reponse can also be interpreted as
13
supersensitivity and has been observed in several tissues (Pollock e£.
Si., 1972; Gardiner si., 1974,* Gibson & Pollock, 1975). 
ii) Subsensitivity
Subsensitivity, or desensitisation of a tissue to a receptor 
ligand is reflected in a rightwards displacement of the dose-response 
curve for that compound (Rang & Ritter, 1969). However, a reduction 
in the maximum response can also be interpreted as a subsensitivity, 
together with, or in the absence of, a rightwards displacement of a 
dose-response curve (Waud, 1975).
The term homologous desensitisation is used to describe the 
specific desensitisation which occurs when cells are re-challenged with 
the same agonist used in the initial exposure (Su e£ al» 1976a;b). In 
the case of the (3-adrenoceptors, this type of desensitisation is 
thought to involve the sequestration of the receptors away from their 
effector in the plasma membrane. The sequestered receptors may then 
become down-regulated (Harden, 1983; Perkins & Hertel, 1987).
The term heterologous desensitisation describes the non-specific 
reduction in sensitivity that occurs when cells are incubated with one 
agonist and subsequently found to the subsensitive not only to that 
agonist, but to several others (Su .££. 1976a;b). Heterologous
desensitisation involves functional uncoupling of receptors in the 
absence of sequestration or down-regulation (Harden, 1983).
The analysis of drug-receptor interactions using classical 
pharmacological techniques in isolated tissues or iji situ with perfused 
organs can be prone to limitations. The use of direct receptor 
labelling techniques has several advantages over more traditional 
pharmacological techniques, such as minimising the problem of drug- 
receptor equilibrium and eliminating the effects of drugs distal to the 
receptor (Minneman & Molinoff, 1980; Nahorski, 1981). However, 
although the measurement of specific binding of radiolabelled high
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affinity agonists and antagonists has demonstrated that alterations in 
the number of receptors may contribute to at least some forms of drug- 
induced desensitisation (Creese & Sibley, 1981; Harden, 1983) f it is 
difficult to draw conclusions from experiments employing only this 
technique. The lack of a final biological response can be a distinct 
disadvantage, particularly in experiments utilising high affinity 
radiolabelled antagonists which, unlike agonists, have little or no 
intrinsic activity. Such ligands are, therefore, of limited value in 
detecting any alterations in the mechanisms linking receptor activation 
to a change in cellular responsiveness.
FACTORS AFFECTING SENSITIVITY CHAMBKS
The endocrine glands release hormones into the bloodstream to 
exert regulatory influences on distant tissues. Two important groups 
of hormones which exert an influence on autonomic function are the 
corticosteroids and the thyroid hormones,
i) Corticosteroids
The adrenocorticosteroids have been implicated in sensitivity 
changes in various smooth muscles. In general, corticosteroid 
administration enhances the response to catecholamines in smooth muscle 
(Gibson & Pollock, 1975), liver (Exton .§£ 1972), adipose tissue
(Brodie .§£ .al,., 1966) and salivary gland (Almagren & Jonason, 1973). 
Acute administration of cortocosteroids inhibits the extraneuronal 
uptake of catecholamines (Iversen & Salt, 1970) and, therefore, 
produces a deviation supersensitivity in some tissues (Kaumann, 1972). 
This is characterised by a leftward shift in the dose-response curve 
for NA, with no effect on the maximum response. Chronic 
administration of corticosteroids enhanced the maximum contractile 
response of the anococcygeus muscle to both NA and ACh (Gibson &
Pollock, 1975). Blockade of extraneuronal uptake produced no
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alteration in the sensitivity of this tissue, suggesting that the 
mechanism of action of chronic corticosteroid administration is not due 
to the blockade of extraneuronal uptake, but may be due to altered ion 
balance (Gibson, 1981). Corticosteroids can alter ionic distribution 
between the intracellular and extracellular space (Beck & McGarry, 
1962). Two of the most important ions involved in smooth muscle 
contraction are Na+ and Ca^+ (Bohr, 1964; Godfraind, 1975). Altering 
the Na+ concentration had a greater effect on muscle contractility, the 
maximum contractile response varying directly with the external Na+ 
concentration. Exposure of tissues to the Na+ pump inhibitor ouabain 
resulted in a supersensitivity similar to that produced by 
corticosteroid administration, suggesting that if Na+ is involved in 
the production of corticosteroid-induced supersensitivity then an 
enhanced intracellular Na+ concentration may be responsible (Gibson & 
Pollock, 1976). Another possible explanation of the enhanced neuro­
effector responses other than changes in ion concentrations is that 
corticosteroids may affect the prostaglandin synthesis pathway (Rascher
1., 1980).
ii) Thyroid Hormones
These hormones, triiodothyronine (T^ ) and thyroxine (T^ ), released 
from the thyroid gland under the control of a pituitary hormone 
thyrotrophin, have multiple effects throughout the body on growth and 
metabolism. They also influence the sensitivity of sympathetically- 
innervated tissues to agonists (Gibson, 1981).
The possibility of a link between the thyroid gland and the 
sympathetic nervous system has been recognised for many years because 
of the striking similarity between the symptoms of hyperthyroidism and 
increased activity of the sympathetic nervous system (Reith, 1865).
Most of the early scientific evidence supported this suggestion, 
neuro-effector responses to catecholamines being enhanced in
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hyperthyroidism and diminished in hypothryoidism (Waldstein, 1966). 
However, the effects of the thyroid hormones on the functioning of 
autonomic neuro-effectors are complex and often contradictory, with not 
all effector organs displaying an increased sensitivity to 
catecholamines in the hyperthyroid state (Macmillan & Rand, 1962).
Most studies on the effects of thyroid hormones on tissue 
sensitivity have involved the use of cardiac tissue. Hyperthyroidism 
increases and hypothyroidism decreases the sensitivity of the heart to 
P-adrenoceptor agonists. Ligand binding studies support these results 
and indicate that hyperthyroidism increases the number of (3- 
adrenoceptors and decreases the number of cc^adrenoceptors, whilst 
hypothyroidism has the opposite effects (Kunos, 1977). Indeed, in 
cardiac tissue, thyroid hormones have complex effects and may alter 
more than the receptor number (Tse jlL., 1980).
The apparent parallel changes in sensitivity and receptor number 
led to the suggestion that there might be a single adrenoceptor that 
can exist in either the a or p state according to the circulating 
levels of Tjj (Kunos, 1977). Here there is a problem. In the heart, 
although both types of adrenoceptor can be found on nerve terminals, 
most of the a-adrenoceptors lie presynaptically on adrenergic and 
cholinergic nerve terminals, while P-adrenoceptors exist mainly on 
postsynaptic non-neuronal tissues. Generally, ligand binding studies 
fail to take account of this fact, which makes it difficult to accept 
the hypothesis of an allosteric change in a single receptor. 
Nevertheless, the ligand binding studies draw attention to the fact 
that some of the alterations in receptor number due to altered thyroid 
status may involve changes in pre- as well as post-synaptic receptors.
Little attention has been focussed on effects of thyroid hormones 
on presynaptic receptors despite the important role of o^-adrenoceptors 
in regulating transmitter release at the sympathetic neuroeffector
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junction (Gillespie, 1980). Part of this study, therefore, 
investigated the effects of altered levels on the sensitivity of 
both pre- and post-synaptic receptors in the mouse deferens.
HOH-ADREHEBGIC. HOH-CHOLIHERGTf! TRAWSMTSSTQH
Hints of the existence of autonomic nerves that release 
transmitters other than ACh or NA can be found in the early literature 
(Langley, 1898; McSwiney & Robson, 1929; Ambache, 1951). Responses 
resistant to blocking drugs were first recognised in the cholinergic 
parasympathetic nervous system because of the availability of the 
powerful muscarinic receptor blocking drug, atropine. As early as 
1898, Langley noted that stimulation of the vagus nerves could produce 
relaxation of the stomach. This relaxation was best revealed after 
blockade of the excitatory action of cholinergic fibres with atropine 
(McSwiney & Robson, 1929). Inhibitory nerves mimicking sympathetic 
nerve stimulation were discovered much later because of the lack of a 
selective potent adrenergic blocking drug. This changed with the 
introduction of adrenergic neurone blocking agents, which were first 
used to analyse the response of the stomach to nerve stimulation.
It was shown that neither the inhibitory response to vagal stimulation 
in the guinea-pig stomach (Martinson & Muren, 1963) nor the inhibitory 
response to transmural stimulation in the guinea-pig, kitten or mouse 
stomach (Paton & Vane, 1963) was blocked. The first suggestion that 
these responses were produced by non-adrenergic inhibitory neurones 
arose from observations that when the responses to both adrenergic and 
cholinergic nerve stimulation had been blocked in the guinea-pig taenia 
coli, large transient hyperpolarisations and relaxations were produced, 
even with single pulses. The possibility that these were due to 
direct stimulation of muscle was excluded since they were abolished by 
tetrodotoxin. They were thus established as inhibitory junction
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potentials (i.j.ps) resulting from stimulation of non-adrenergic, norv- 
cholinergic (NANC) neurones (Burnstock si. si.., 1963; 1964). The
presence of NANC nerves has been reported throughout the 
gastrointestinal tract of many vertebrate species (Burnstock si. al.. 
1966), as well as in other organs, including lung, urinary bladder, 
trachea, oesophagus, anococcygeus, seminal vesicles and parts of the 
cardiovascular system (Burnstock, 1969; Furness & Costa, 1973; 
reviews by Burnstock, 1972; 1979).
The next step was to try to determine the principal transmitter in 
these nerves. Many substances were examined, including 
catecholamines, 5f-hydroxytryptamine (5-HT), adenosine 3*-5' 
monophosphate (cAMP), histamine, prostaglandins, various amino acids 
and some polypeptides. Most were rejected either because they did not 
mimic the nerve-mediated response, or their action was produced via 
stimulation of nerves and not by direct action on smooth muscle. A 
purine nucleotide, probably adenosine triphosphate (ATP), emerged as 
the most likely contender (Burnstock fii. si.., 1970; 1972). This 
finding was followed by a systematic series of experiments to 
investigate whether or not ATP satisfied the criteria necessary for 
establishing a substance as a neurotransmitter, namely:
synthesis and storage of transmitter in nerve terminals, 
release of transmitter during nerve stimulation, 
postjunctional responses to exogenous transmitter that 
mimic responses to nerve stimulation, 
enzymes that inactivate the transmitter and/or an uptake 
system for the transmitter or its breakdown products, and 
drugs that produce parallel blocking Or potentiating effects 
on the responses to both exogenous transmitter and nerve 
stimulation.
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On the basis of the evidence which was obtained from these studies 
(see reviews by Burnstock, 1972; 1979; 1981), the purinergic nerve 
hypothesis was formulated. In 1971, nerves, utilising ATP as the 
principal transmitter, were termed ’purinergic1 (Burnstock, 1971) and a 
tentative model for the storage, release and inactivation of ATP for 
purinergic nerves was proposed (Burnstock, 1972). It was suggested 
that following release, that fraction of ATP not bound to receptors is 
rapidly broken down, possibly by extracellular enzymes. The 
penultimate product, adenosine, is taken back into the nerve endings 
for resynthesis to ATP. Any adenosine not taken up in this way is 
broken down to inosine, which is pharmacologically inactive, cannot be 
taken up by nerves and leaks into the circulation. This system is 
comparable to that for ACh, where the extracellular enzyme 
cholinesterase rapidly breaks down the released transmitter, and the 
end product choline is reincorporated into the nerve and resynthesised 
to ACh, ready for release.
Since the purinergic nerve hypothesis was postulated there has 
been much debate, with evidence presented both for and against 
(Burnstock, 1979; Stone, 1981; Gillespie, 1982). Although ATP 
mimics well in most tissues the response to non-^adrenergic inhibitory 
nerves, there are discrepancies, mainly in the evidence concerning the 
stomach and oesophagus (Gillespie, 1972; Ohga & Taneika, 1977; Daniel 
et al.. 1979). However, systematic studies by electronmicroscope 
suggested that it was unlikely that all NANC nerves were a single 
population with only one transmitter. Up to nine morphologically 
distinguishable types of neurones were revealed in the enteric 
plexuses, including some nerve profiles containing a complex mixture of 
vesicles, suggesting that they may contain more than one transmitter 
(Gabella, 1972; Cook & Burnstock, 1976). These findings were 
followed by several investigations based on the new histochemical
20
approach which followed the advances in peptide chemistry. With pure, 
identified peptides, highly selective immune sera were produced, and 
these in turn were used for fluorescence histochemistry. Autonomic 
nerves containing many polypeptides have been described (Hokfelt al.. 
1980). (For a list of the substances currently considered to be 
transmitters or putative transmitters in autonomic nerve fibres see 
Burnstock, 1986).
CO-TBAHSMISSIOW
A widely held belief about the organisation of the nervous system 
was that each nerve cell makes and releases only one transmitter.
This has been described as 'Dale’s Law*. Dale, in fact, never 
suggested that neurones contain only one neurotransmitter, but proposed 
that each neurone releases the same neurotransmitter at all its 
synapses (Dale, 1935). ’Dale’s Law’ was probably widely accepted 
because it fitted in with the belief prevalent for many years that 
efficient transmission required only a single stimulatory or inhibitory 
transmitter.
The suggestion that some nerve cells store and release more than 
one transmitter was based largely on the early studies of Burn and Rand 
(1965). According to their hypothesis, ACh is present together with 
NA in adrenergic axons and forms an intermediate link between nerve 
impulses and the release of NA from the nerve terminals (Burn & Rand, 
1965). There is now considerable experimental support for the co­
existence of peptides or purine nucleotides together with classical 
neurotransmitters (Chan-Palay & Palay, 1984). It is clear that 
’Dale’s Law' has been invalidated by the discovery of numerous examples 
of co-existence of putative neurotrans-mitters (see O’Donohue qXl al.f 
1985).
Much of the evidence for co-transmission in sympathetic nerves has 
come from years of experimental study of the vas deferens.
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THE VAS DEFERENS
The vas deferens is the duct which carries spermatozoa from the 
testes to the urethra. It is composed of three layers of smooth 
muscle, an outer and inner longitudinal layer surrounding an inner 
circular layer. As in the muscle layers of most visceral tissues, 
muscle cells in the vas deferens are arranged in branching bundles of 
irregular cross-section surrounded by connective tissue sheaths. The 
muscle bundles rather than the individual muscle cells are the effector 
units (Bennett & Burnstock, 1968). In most mammals the vas deferens 
is probably the most densely innervated muscle in the body. It is 
supplied with an autonomic ground plexus in which postganglionic axons 
branch to form preterminal axons from which transmitter is released 
(Sjostrand, 1965; Burnstock, 1970). Preterminal axons are
predominantly non-myelinated, surrounded by a Schwann cell sheath and 
beaded. The beaded appearance is due to the varicosities of 
functional nerve endings which are the anatomical sites of release.
In the varicose regions of these axons (0.5-1 in diameter and 1-3 
long), which are packed with vesicles and mitochondria, the Schwann cell 
sheath is often incomplete, leaving them naked (Burnstock, 1970).
The vas deferens has the highest NA content of any tissue, varying 
between 5 and 20 Hg/g of tissue in several different species 
(Sjostrand, 1965; Blakeley .§£ 1970). A dense adrenergic
innervation has been demonstrated by the use of histochemistry (Falck 
et al.. 1965). It has, however, been known for some time that the 
motor response to nerve stimulation is resistant to a-adrenoceptor 
antagonists (Boyd .§£. ai.., 1960).
In early experiments on adrenergic neurotransmission, the isolated 
vas deferens was stimulated for short periods at regular intervals.
It was generally believed that the motor transmitter, NA, elicited a 
simple monophasic mechanical response. However, using longer periods
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of stimulation, Swedin (1971) uncovered a secondary component of the 
mechanical response in rat and guinea-pig vasa. The motor response to 
field stimulation was now seen to be more complex than previously 
considered, consisting of an initial rapid contraction, or 'twitch1, 
which declined, to be replaced by a slower, better-maintained, 
'secondary' response. The twitch response, unlike the secondary 
component, was shown to be resistant to oc- and {3-adrenoceptor blocking 
drugs and reserpine pretreatment. Only the neurone blocking drugs 
guanethidine and bretylium were capable of abolishing both phases of 
the contractile response. Swedin (1971) proposed that NA, on release 
from adrenergic nerves, rapidly reaches high concentrations in the 
narrow neuromuscular gap and this effectively stimulates the local 
junctional receptors. On sustained stimulation, the continuously 
released surplus of NA diffuses out of the narrow neuromuscular cleft 
to stimulate extrajunctional receptors, thereby mediating the prolonged 
secondary phase of the mechanical response.
Ambache and Zar (1971) reported a very low sensitivity of the 
longitudinal muscle to the motor action of NA, and an inhibitory effect 
of both sympathomimetic drugs and NA on the nerve-stimulated twitch 
response. The twitch height failed to be depressed either by combined 
block of a- and p-adrenoceptors, or by irreversible antagonism with PBA 
which blocked more than 1000 twitch-matching doses of NA. In 
preparations from animals pretreated with reserpine, the motor response 
to field stimulation was unaffected, and exogenous NA inhibited the 
twitch responses of the field stimulated vas deferens. From their 
evidence, Ambache and Zar concluded that motor transmission was 'non- 
adrenergic'. The inability of a- and P-adrenoceptor blocking drugs 
and the ability of NA to inhibit the twitch response in the guinea-pig 
vas deferens also led von Euler and Hedqvist (1975) to support the 
conclusion reached by Ambache and Zar (1971). The physiological
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function of the dense adrenergic innervation was postulated to be a 
modulator for the non-adrenergic motor response, the NA acting 
prejunctionally on the non-adrenergic neurones to inhibit the release 
of the unknown transmitter (Ambache j&l,, 1972).
Although sixteen years have passed since the first conflicting 
reports (Ambache & Zar, 1971; Swedin, 1971)» the nature of motor 
transmission in the vas is still under debate. Whilst the use of 
drugs has greatly enhanced our understanding of transmitter mechanisms 
in the vas, many observations remain difficult to explain.
Several experimental observations suggest that the initial phase 
of the contractile response to field stimulation in vasa from various 
species is mediated by ATP acting on P2-purinoceptors and may be termed 
'purinergic1. First, the time course of the first component is 
mimicked by exogenous ATP, not NA (Sneddon & Westfall, 1984).
Secondly, it is blocked by the P2-purinoceptor antagonist arylazido 
aminopropionyl ATP (ANAPP^) (Fedan ,g£. sJL$ 1981; Sneddon .§£ £1, 1982; 
Sneddon & Westfall, 1984). Thirdly, it is abolished in tissues 
desensitised to ATP by exposure to the stable analogue a,(3-methylene 
ATP (a,f3-MeATP) (Meldrum & Burnstock, 1983). The underlying 
electrical event, the excitatory junction potential (e.j.p.), also 
exhibits these purinergic characteristics. First, local application 
of ATP but not NA can exactly mimic the time course of the e.j.p. 
(Sneddon & Westfall, 1984). Secondly, e.j.ps are blocked by ANAPP^ 
(Sneddon et al.. 1982; Sneddon & Westfall, 1984) and by a, (3-MeATP 
(Sneddon & Burnstock, 1984) but not by a-adrenoceptor blockers.
Thirdly, e.j.ps are not reduced by pretreatment with reserpine (Sneddon 
& Westfall, 1984).
The second component of the response to field stimulation has been 
shown to be adrenergic by all the pharmacological tests employed. It 
is blocked by a-adrenoceptor antagonists (McGrath, 1978; Sneddon &
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Westfall, 1984; Sneddon si,, 1984), inhibition of NA release by 
stimulation of prejunctional a-adrenoceptors with lysergic acid 
diethylamide (LSD) (Booth si.., 1978) and depletion of NA stores with 
reserpine (Booth .&1., 1978; Sneddon & Westfall, 1984). Further 
evidence for the existence of two transmitters comes from experiments 
utilising the calcium channel antagonist nifedipine, which eliminates 
the initial twitch response leaving the second component intact (French 
& Scott, 1981). Since, on examination of the electrical events 
underlying the mechanical response, nifedipine was found to abolish the 
smooth muscle action potential, leaving the second component intact, 
there appears to be a fundamental difference between the two types of 
response to nerve stimulation in the vas deferens (Blakeley e£ al.. 
1981). Whether or not the two transmitters are contained in a single 
or in separate nerves is still doubtful, since selective destruction of 
sympathetic nerves by 6-hydroxydopamine (6-OHDA) apparently inhibits 
only the adrenergic component in some studies (Booth _e£ .&1., 1978;
Brown £& jil.., 1983) but inhibits both components in others (Fedan 
1981; French & Scott, 1983).
However, it has been suggested that NA may be the sole 
transmitter, producing its contractile effects through two processes, 
the first involving e.j.ps which summate to initiate propogated action 
potentials but does not involve classical a-adrenoceptors. These y 
receptors may be present in a number of sympathetically-innervated 
tissues (Hirst & Neild, 1980; 1984). The second process does not 
involve e.j.ps or propogated action potentials but is mediated by a^- 
adrenoceptors.
Most of the experimental evidence suggests that the response to 
field stimulation in the vas deferens can be accounted for largely in 
terms of the combined effects of NA and ATP, although a third factor 
appears to participate in transmission. After the ’removal' of both
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NA- and ATP-mediated components, a small residual contraction remains. 
It has been postulated that the recently discovered 36-amino acid gut- 
brain peptide neuropeptide Y (NPY) (Tatemoto, 1982) may mediate this 
response (Stjarne & Xstrand, 1985; Stjarne .al,* 1986). A high 
level of NPY-like immunoreactivity (NPY-LI) has been shown to exist in 
vasa deferentia of several species (Lundberg al si.., 1982; 1983; 1984). 
Although NPY has only weak contractile effects on the smooth muscle of 
the vas, it greatly potentiates the contractile effects of exogenous NA 
and a, p-MeATP, thus NPY may have additional contractile effects 
expressed through its co-transmitters. Exogenous NPY depressed the 
twitch phase of the field stimulation-evoked contractile response of 
mouse and rat vasa, but not the contraction evoked by exogenous NA 
(Allen el si., 1982; Lundberg si 1982). NPY also depressed the
secretion of (^H)-NA and both phases of the contractile response to 
field stimulation in the rat vas deferens, suggesting that NPY inhibits 
the secretion of both NA and the putative transmitter ATP (Lundberg & 
Stjarne, 1984).
While the mechanism by which nerve stimuli evoke secretion of 
quanta of ATP and NA from individual varicosities of the guinea-pig and 
mouse vasa deferentia is beginning to be understood (Cunnane & Stjarne, 
1982; 1984; Stjarne, 1985; Stjarne & Xstrand, 1984; 1985), the 
characteristic features of the secretion of endogenous NPY from these 
sympathetic nerves are not yet known. Experiments in the pig spleen, 
however, have shown that splenic nerve stimulation at a low continuous 
frequency releases mainly NA, while intermittent activation with high 
frequency bursts preferentially releases NPY-LI (Lundberg al .si., 1986). 
The nerve stimulation-evoked release of NPY-LI was enhanced following 
either a-blockade with phentolamine or NA depletion after resperine 
pretreatment. This was especially evident at low frequencies of
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stimulation suggesting that NA exerts an inhibitory prejunctional 
influence via a-adrenoceptors on the release of NPY-LI (Lundberg 
1986; St jarne £_fc. .gX., 1986).
The dense adrenergic innervation of their smooth muscle layers has 
led to the widespread use of rodent vasa deferentia in the study of 
adrenergic mechanisms. In particular, nerve-induced contractions have 
proved useful in assaying compounds which act at prejunctional 
receptors to inhibit transmitter release, for example, opioid receptors 
in the mouse vas deferens (Henderson .§£ gX*» 1972). Such studies are 
possible despite incomplete understanding of the neuro-transmission 
process. However, the wealth of information obtained over the past 
sixteen years on neurotransmission in the vas deferens indicates that, 
much as we would like to simplify the biological systems we study, 
inconsistencies cannot be ignored in order to force observations into 
generally accepted hypotheses.
A tissue possessing such complexities as the vas deferens requires 
a combination of techniques to be integrated in providing a clearer 
understanding of its activity. This study set out to determine, using 
a combination of well-established and some novel techniques :-
1) If, indeed, there is evidence for the existence of more than
one transmitter, are they contained in a single nerve or 
in separate nerves?
2) How does altering the stimulation parameters affect the release
of the co-transmitters?
3) Are the co-transmitters involved in mutual regulation of release
by a presynaptic action?
4) What effect does altering the circulating levels of Tj^ have
on the sensitivities of pre- and post-synaptic receptors?
MATERIALS AND METHODS
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INVESTIGATION INTO THE INFLUENCE OF THYROID HORMONES ON 
PRE- AND POST-SYNAPTIC SENSITIVITY IN THE MOUSE VAS DEFERENS
i) Preparation of Tissues
Adult, male, T.O. mice (25-30 g) were anaesthetised with 
halothane and killed by decapitation. The blood was collected, 
allowed to clot and then centrifuged to obtain the serum, which was 
frozen until required for radioimmune assay. The vasa deferentia were 
excised, placed in a petri-dish containing Krebs-bicarbonate solution 
of the following composition (mM): NaCl (118.1), KC1 (4.7), MgSO^
(1.0), Kf^POjj (1.2), CaCl2 (2.5), NaHC03 (25.0), glucose (11.1), and
the adjoining blood vessels and connective tissues were removed. Each
tissue was mounted vertically (epididymal end uppermost) with an 
initial resting tension of 500 mg, in a 25 ml double-jacketed organ 
bath containing Krebs solution. This was maintained at 37°C and 
gassed continuously with 95% 02 and 5% C02. Changes in tension of the 
isolated tissues were recorded isometrically with a Grass FT03 force- 
displacement transducer and displayed on a Grass Model 7 polygraph,
ii) Investigation of. Presynaptic Changes
To examine any thyroid-induced changes in presynaptic receptor 
sensitivity, the vasa deferentia from treated and untreated mice were 
stimulated electrically by field stimulation through silver ring 
electrodes with a Grass S88 stimulator. Trains of stimuli were 
achieved using the following parameters: 20 Hz; 500 p.s pulse width;
500 msec, duration; every 100 sec., supramaximal voltage. Field 
stimulation causes the release of transmitter from nerve endings. In 
the mouse vas deferens, the presynaptic a2-adrenoceptors and opiate 
receptors can inhibit this release and can, therefore, inhibit the 
tissue response to field stimulation. The selective <*2-adrenoceptor 
agonist, clonidine, and opiate receptor agonist, morphine, were used to 
determine the sensitivity of these presynaptic receptors. Increasing
28
concentrations of agonist were added to the organ bath, each dose being 
washed out after maximum inhibition of the tissue response to a single 
dose was achieved. The tissue was allowed to recover before the 
addition of a subsequent dose,
iii) Investigation of Postsvnaptic Changes
The responses of isolated vasa deferentia from treated and 
untreated animals to the -adrenoceptor agonist, NA, and the 
muscarinic cholinoceptor agonist, carbachol, were examined to determine 
any thyroid-induced changes in postsynaptic sensitivity in smooth 
muscle. Increasing concentrations of agonist were added to the bath, 
each concentration remaining in contact with the tissue for 30 sec. 
before being washed out and 5 min. being allowed to elapse between drug 
additions. Responses to each concentration were measured as grammes 
tension developed by the tissue and as a percentage of the maximum 
response.
iv) Rariinlinninp Assay of Free Serum Thvroxine Levels
Radioimmune assay of serum thyroxine (T^ ) allowed the 
effectiveness of the pretreatment to be monitored. An Amersham 
Amerlex T^ RIA kit (IM3050) was used for the immune assay of free T^ in 
the serum obtained from treated and untreated mice. This method 
depended upon the competition between 12^I-T^ and free T^ in the serum 
for a limited number of binding sites on a T^-specific antibody. The
Ipc
proportion of the I-T^ bound to the antibody was inversely related 
to the concentration of free T^  present in the serum. Standards 
(containing known amounts of T^ ) and the serum samples were mixed with 
both 2^-*I-Tjj and T^-specific antibody suspension and then allowed to 
stand for 45 min. Centrifugation (2000 x g, 10 min., room 
temperature) produced a pellet of antibody with its bound 12^I-T^ and 
T|j beneath a liquid supernatant. The supernatant was discarded and 
the pellet counted in a gamma counter. A standard curve was
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constructed showing the concentration of free versus -'I counts, 
from which the free content of the serum samples could be obtained,
v) Measurements and Statistics
Dose-response curves, using both absolute responses in grammes 
tension developed by the muscles and with responses expressed as a 
percentage of the maximum response, were constructed for each agonist. 
All tissues, whether treated or untreated, were exposed to the four 
agonists in a random order. Each response was expressed as a mean 
with a standard error of the mean (x - S.E. mean). To compare 
results, Student’s t-test was used. Levels of significance:
* 0.05>P>0.01; ** 0.01>P>0.001 ; ***P<0.001.
(3H)-noradrenaline overflow experiments
Adult, male, T.O. mice (25-30 g) (unless specified), were stunned 
and killed by exsanguination. Vasa deferentia were dissected, freed 
from connective tissue and transferred to 0.5 ml of Krebs bicarbonate 
buffer containing 12 pCi of (^H)-noradrenaline ((^H)-NA), previously 
gassed with a mixture of O2, 9556/002, 5$. Vasa were incubated in the 
radioactive solution (37°C, 30 min.), inserted into silver ring 
electrodes and transferred to organ baths (2 ml capacity), where they 
were attached to Stratham force displacement transducers (resting 
tension 0.5 g) to record motor responses isometrically. Vasa were 
continuously superfused with Krebs solution (37°C, 4 ml/min., 1.5 hr.) 
to remove loosely bound (^H)-NA not taken up into nerves.
At the end of this preliminary washing period, the superfusion was 
stopped and, with the organ baths filled with Krebs solution, vasa were 
stimulated with a Grass stimulator (model S88) at a frequency of 20 Hz 
for a period of 5 sec., pulse width 0.5 msec., supramaximal voltage. 
Motor responses were displayed on a Grass polygraph (model 7). At the 
end of each period of stimulation and at intervals between
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stimulations, the contents of the organ baths were collected in liquid 
scintillation vials containing 10 ml of Ecoscint (National 
Diagnostics). The radioactivity in each vial was counted in a Packard 
Tricarb liquid scintillation counter and the fractional release 
obtained with each stimulation was calculated.
All counts were corrected for quenching and the results expressed 
as d.p.m. The (^H)-NA released into the organ baths during 
stimulation was separated from its metabolites by column chromatography.
Apparatus for Overflow Experiment
Oxygenated Krebs
Pump
Heating
Coil
to Transducer
to Water 
Heater
Electrode 
Vas- - - -
Organ
Bath Collecting
Beaker
FIGURE 1. Diagram of apparatus used for overflow experiments.
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METABOLISM STUDIES
Alumina was treated according to the method of Crout (1961) and 
washed with 0.2 M sodium acetate before drying. Dowex 50W x 4 (200- 
400 mesh) was washed several times with 2 M NaOH (containing Na-EDTA) 
at 50°C until the supernatant was clear, washed with H20, 2 M HC1, H20 
and, finally, equilibrated with 0.01 M HC1. Columns used for 
chromatography were 0.5 cm in diameter and stoppered with cotton wool. 
200 mg of activated alumina was used and washed before use with 5 ml 
0.2 M sodium acetate (pH 8.2), Dowex columns were filled to a height of 
1.5 cm (0.5 ml) with resin and washed with 2 ml H20.
10 [ig of unlabelled NA and of each NA metabolite were added as 
carrier to each sample. The pH of the samples was adjusted to 8.2-8.4 
with 0.5 M Tris buffer (pH 8.2) then immediately added to the column. 
After addition, the column was washed through with a further 1 ml 0.2 M 
sodium acetate and 2 ml H20. The effluent and washing contained the 
0-methylated metabolites 3-methoxy-4-hydroxyphenylglycol (MOPEG), 3 
methoxy-4-hydroxymandelic acid (VMA) and normetanephrine (NMN).
The (^H)-NA and (^H)-DOPEG fraction was then eluted with 3.5 ml
0.2 M acetic acid. After washing the column with 4 ml 0.5 M acetic 
acid, which elutes approximately 5% of both NA and D0PEG, the 
deaminated acid, DOMA, was eluted with 3 ml 0.2 M HC1.
(^H)-NA was separated from the (^H)-DOPEG by means of the strong 
cation exchange resin Dowex-50W x 4. 2 ml of the (^H)-NA/(^H)-DOPEG
fraction was poured onto the column and washed through with 2 ml H20.
The effluent and washings contained D0PEG. After washing with a 
further 2 ml H20, which was discarded, the NA was eluted with 3 ml 3 M 
HC1.
The O-methylated fraction was separated using Dowex-50W x 4 
columns. The O-methylated deaminated metabolites (VMA and MOPEG) 
passed through the column and were collected in the effluent. NMN was
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retained by the Dowex and subsequently eluted with 2 ml 6 M HCl/ethanol 
(1:1 v/v).
1 ml of each separated fraction was added to 10 ml of Ecoscint in 
a counting vial and radioactivity was measured in a Packard Tricarb 
liquid scintillation counter.
The method of separation was essentially that of Graefe et al. 
(1973) and Nicol (1975), with the following modifications. Volumes of 
eluates were increased so that aliquots could be taken for counting 
before column separation. This allowed corrections for recovery to be 
made in each sample. The volume of 0.2 M acetic acid used to elute 
the NA/DOPEG fraction from the alumina column was increased from 2 ml 
to 3.5 ml and the 0.2 M HC1 used for elution of (^H)-DOMA was increased 
from 2.5 to 3 ml. The concentration of HC1 required to elute (^H)-NA 
was increased from 2 M to 3 M and the volume from 2 to 3 ml. These 
alterations were made to ensure complete recovery of (^H)-NA.
Calculation of metabolism results
The amount of radioactivity appearing in each of the metabolite 
samples compared to that in the sample before separation gave an 
indication of the recovery and efficiency of each column. The 
recovery for the alumina column was 87.^  - 1.7 % (n = 8) and for the 
Dowex columns 98.6 - 4.5% and 91.S - 1.8 % (n = 8) respectively.
The amount of (^H)-NA and (^H)-metabolites present in the pre­
stimulation sample were subtracted from the amount in each sample 
obtained after nerve stimulation.
(3h)-NA and its metabolites were expressed as a percentage of the 
total present in the samples.
Results were expressed as mean - standard error of the mean. 
Significance was assessed by Student*s t test.
SAMPLE 
(2ml, pH 8-2-M
| | p  AIJ3* (200mg) 
EFFLUENT I ELUATE
+  Wash 
1ml 0'2M CHJIOONa 
2mlHz0
3ml aliquot
EFFLUENT,
-h Wash 
2ml HO
VMA/MOPEG
Wash
3'5ml 0‘2M CHJLOOH
2ml aliquot
Hi)
DOWEX 50WX  4  
(0'5ml, pH 1-2)
ELUATE
2ml 6MHCI--EWH 
1 1 -1 )
EFFLUENT/
-f- Wash 
2ml Hz0
NMN DOPEG
3ml 0'2MHCl
ELUATE
(Hi)
2ml FLOI
Discard
(iv)
3ml 3M HCl
NA DOMA
FIGURE 2. Flow diagram of the chromatographic separation of (^H)-NA 
from its metabolites. 2 ml samples were applied to the alumina 
colums. The effluent and washings contained COMT metabolites. The 
acetic acid eluate contained the NA and DOPEG. The HCl eluate from 
the alumina contained DOMA. The COMT metabolites were separated by a 
D0WEX-50W x 4 column into VMA/MOPEG and NMN. The NA-DOPEG fraction 
was also separated by a DOWEX-50W x 4 column into DOPEG and NA.
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IN VIVO EXPERIMENTS
Male Wistar rats (200-250 g) were anaesthetised with 
pentobarbitone (60 mg/kg, i.p.). In each animal the trachea was 
cannulated to allow respiration to be maintained artifically with a 
Palmer pump. In addition, the carotid artery and the femoral vein 
were cannulated to permit blood pressure (B.P.) to be recorded and 
drugs to be administered intravenously. An electrode consisting of a 
stainless steel tube within a Teflon tube (Gillespie et. ill., 1970) was 
inserted between thoracic vertebrae Tg and Tg and pushed down the 
spinal canal to the point of furthest penetration in the sacrum. The 
length of the stimulating electrode extruded from the shielding Teflon 
tube could be varied but was usually 1-2 cm, so that the spinal nerves 
leaving the column from down to the sacrum were stimulated. A 
brass rod, used as an indifferent electrode, was inserted under the 
skin, dorsal to and along the length of the vertebral column. 
Tubocurarine was administered (1 mg/kg, i.v.) to block neuromuscular 
transmission and prevent contractions of voluntary muscle interfering 
with responses of the vas deferens.
One vas deferens was exposed and attached by means of a thread and 
sewn through the muscle to a Grass FT03 force displacement transducer. 
The resting tension was adjusted to 1 g and 2 platinum electrodes were 
placed around the vas to permit electrical field stimulation of the vas 
in situ.
With the spinal electrode exposed from down to the sacrum, 
supramaximal stimulation with 0.5 ms pulses at various frequencies 
caused the vas to contract, with either no effect or, occasionally, a 
small depressor effect on B.P. The motor response of the vas to 
stimulation of the spinal nerves was similar to that produced by field 
stimulation and was biphasic when the chart recorder speed was fast.
If the length of electrode exposed within the vertebral canal was
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increased by withdrawing the Teflon shielding, stimulation produced 
large pressor responses, which developed more slowly and outlasted the 
contractile response of the vas. In these experiments, the motor 
response of the vas was poorly maintained and the decay of this 
response coincided with the onset of the pressor responses, which was 
caused by stimulation of the spinal outflows to the adrenals. This 
pressor response was blocked by phentolamine (1 mg/kg, i.v.), which 
simultaneously prolonged the motor response of the vas. Throughout 
these studies, the position of the electrode within the spinal canal 
was monitored radiographically.
NS
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FIGURE 3. Schematic representation of the iji situ anaesthetised rat 
preparation. t:S‘,Vasa were field stimulated by means of 2 platinum 
electrodes placed around the vas. KI«S;Nerve stimulation was obtained by 
an electrode inserted into the spinal canal and the stimulation of the 
spinal motor outflows to the vas.
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PHOSPHOLIPID EXTRACTION AND SEPARATION OF PHOSPHATIDIC ACID (PA)
BY THIN LAYER CHEOMATOGRAPHI
Male Porton mice (25-30 g) were stunned and killed by 
exsanguination. Vasa deferentia were dissected, freed from connective 
tissue, dried on filter paper and weighed. A numbered thread was 
attached to each of the vasa, which were transferred to test-tubes 
containing 2 pCi of [^P]-orthophosphate per vasa in 3 ml of Hepes 
buffer (mM:NaCl 11.4, KC1 4.7, MgCl2 1.2, glucose 11.1, Hepes 10.1, pH 
adjusted with NaOH to 7.2). Vasa were incubated in this radioactive 
solution (37°C, 2 hr.), removed and washed 3times in 250 ml of 
Krebs buffer, previously gassed with a mixture of 02, 95?/C02, 5% to 
remove loosely bound [^^P]-orthophosphate.
Experiments were carried out in two ways. In some experiments 
vasa were inserted into silver ring electrodes, transferred to organ 
baths each containing 2 ml of Krebs buffer (37°C) and attached, with a 
resting tension of 0.5 g, to a Stratham force displacement transducer. 
These vasa were stimulated (20 Hz, 5 sec., pulse width 0.5 msec., 
supramaximal voltage) with a Grass model S88 stimulator. At the peak 
of each field stimulation-induced motor response, which was displayed 
on a Grass model 7 polygraph, each vas was removed and plunged into 
liquid nitrogen. In other experiments vasa were not subjected to
field stimulation but were exposed to agonists. In these studies vasa
were incubated in Krebs solution containing agonists (37°C, 5 min.) and
then plunged into liquid nitrogen.
Each frozen vas was transferred to 2 ml of a mixture of 
chloroform/methanol/10 M-HC1 (25:50:4, v/v/v) in a glass Potter- 
Elvehjem homogeniser, in which the vas was homogenised. To each 
homogenate was added 1.25 ml of chloroform and 2.05 ml of water to 
partition the aqueous and organic phases. The contents of each tube 
were vortexed and centrifuged (1000 x g, 15 min.) to separate the
aqueous and organic layers. The lower (chloroform) layer, which 
contained the extracted phospholipids from each sample, was carefully 
transferred using a Pasteur pipette to a test-tube and reduced to 
dryness at 40°C under oxygen-free nitrogen gas.
The extracted lipids from each sample were redissolved in 75 pi of 
a mixture of chloroform and methanol (9:1, v/v) and spotted on to 
silica gel thin layer chromatography (t.l.c.) plates (10 cm x 10 cm) 
for two dimensional separation of phospholipids according to the 
procedure described by Yavin and Zutra (1977). Briefly, this t.l.c. 
system employs a basic solvent (chloroform/methanol/aqueous methylamine 
(40$) 130:60:150 v/v/v), neutralisation with HCl fumes, an acid ether 
wash in the second dimension with diethylether/glacial acetic acid 
190:10, v/v, and an acidic solvent (chloroform/acetone/methanol/glacial 
acetic acid/water 100:40:20:30:10, v/v/v/v/v) also in the second 
dimension. In order to facilitate identification of the [^^P]-PA, 
unlabelled carrier PA (10 pg/ml) was added to each plate. Individual 
spots were detected by exposing the plates to iodine vapour and the 
spot corresponding to PA was scraped into liquid scintillation vials 
each containing 10 ml of Ecoscint (National Diagnostics). The [^2P] 
radioactivity was quantified by liquid scintillation spectroscopy. 
Results were expressed as % change in [^2P]-PA formation over controls. 
Means were compared using Student's t test.
FIGURE 4. Schematic representation of phospholipid separation by two^  
dimensional thin layer chromatography. Phospholipids identified 
by iodine staining are indicated. 0 - Origin; PI - phosphatidyl 
inositol; PC - phosphatidyl choline; PA - phosphatidic acid;
PS - phosphatidyl serine; PE - phosphatidyl ethanolamine;
P-LPE - plasmalogen lyso-phosphatidyl ethanolamine; SPM - sphyngo- 
myelin; LPE - lyso-phosphatidyl ethanolamine; NL - neutral lipids.
1) chloroform methanol methylamine (40%) (130:60:15 v/v/v)
2) diethyl ether acetic acid (190:10 v/v)
3) chloroform acetone methanol acetic acid water (100:40:20:30:10 
v/v/v/v/v)
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Drugs Used
The drugs used during the project were adenosine 5f triphosphate 
(Sigma), a, (3-methylene ATP (Sigma), L-ascorbic acid (Sigma), atropine 
sulphate (Sigma), carbamoylcholine chloride (Sigma), clonidine 
hydrochloride (Sigma), desipramine hydrochloride (Sigma), dL-3,4- 
dihydroxymandelic acid (Sigma), dL-3,4-dihydroxyphenylglycol (Sigma), 
Tyr-D-Ala-Gly-n-Me-Phe-Gly-O/enkephalin (Cambridge Research 
Biochemicals), 6-hydroxydopamine hydrobromide (Sigma), dL-4-hydroxy-3- 
methoxymandelic acid (Sigma), bis-4-hydroxy-3-methoxyphenylglycol 
(Sigma), morphine hydrochloride (MacFarlan Smith), naloxone 
hydrochloride (Sigma), L-(7,8-^H) noradrenaline (Amersham), L- 
noradrenaline bitartrate (Koch-Light), dl-normetanephrine hydrochloride 
(Sigma), 17,P-oestradiol (Sigma), pentobarbitone sodium (May and 
Baker), phenoxybenzamine hydrochloride (Smith, Kline and French), 
trans-2-phenylcyclopropylamine hydrochloride (Sigma), phentolamine 
mesylate (Ciba), prazosin hydrochloride (Pfizer), reserpine (Sigma), 
tetrodotoxin (Boehringer), L-thyroxine (Sigma), d-tubocurarine 
(Wellcome), tyramine hydrochloride (Sigma), yohimbine hydrochloride 
(Sigma).
The drugs were prepared in 0.9$ NaCl, except when otherwise 
stated.
L-(7,8-^H)-noradrenaline (8-14 Ci mmol- )^ supplied in 0.02 M 
acetic acid:ethanol (9:1 v/v), was resuspended in distilled water 
containing ascorbic acid (5.7 x 10~^ M) to prevent breakdown of the 
catecholamine.
Reserpine was dissolved in a 4$ solution of L-ascorbic acid.
Phenoxybenzamine and 17,p-oestradiol were made up in absolute 
alcohol, but were never added in volumes greater than 0.25 |il/ml of 
Krebs solution.
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ANIMAL PRETREATMENTS 
I L-Thyroxine (L-T^)
L-Tjj was administered orally in the drinking water. Preliminary 
studies indicated that a 25 g mouse drinks 5 ml of water per day, so 
L-Tjj was added to the water to give a solution of 100 mg/1. This gave 
each mouse a dose of 20 mg/kg/day. The mice were treated for 2 
weeks before being examined.
II .6—Hydroxvdonami ne (6-PHDA)
6-OHDA was administered to mice and rats as follows
Experiments were carried out on days 4 and 5.
111 + 6-OHDA
L-Tjj was administered orally in the drinking water to give mice a 
daily dose of 20 mg/kg. 6-OHDA was administered during the period of 
treatment with L-T^ on day 1 (2 x 50 mg/kg i.p.), day 4 (2 x 100 mg/kg
i.p.) and on the last day of treatment with L-T^ i.e. 2 weeks 
(2 x 100 mg/kg i.p.).
The mean volume of water drunk by mice was determined and this 
volume was used to calculate the concentration of drug that needed to 
be added to the drinking water to provide the mice with the required 
drug dosage. Since the volume of drug solution drunk and, therefore, 
the amount of drug administered varied from day to day, the doses 
administered were correct only to within - 8$ of the stated doses.
ReLSe* ‘ ' I - • - ^oWouiS’,—
i) 2 x 50 mg/kg (i.p.) on day 1
ii) 2 x 100 mg/kg (i.p.) on day 3
R E S D L T S
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PART I
RESPONSES OF HOUSE ISOLATED VASA DEFERENTIA TO ELECTRICAL 
FTEID STIMULATION. AND THE EFFECTS OF ACUTE AND CHRONIC DRUG 
ADMINISTRATION ON THESE RESPONSES
Field stimulation of the mouse vas deferens produced a biphasic 
response, consisting of an initial fast component followed by a more 
prolonged contraction (Fig. 5a). The first component was enhanced and 
the second component inhibited by phentolamine (10”  ^ M) (Fig. 5b).
Morphine (10“  ^M, 10“5 M) inhibited the first component and 
potentiated the second component of the biphasic contractile response 
evoked by field stimulation (Figs. 6, 7). Both the inhibitory effect 
of morphine on the first component and the enhancing effect of morphine 
on the second component were antagonised by naloxone (10”  ^M) (Fig. 7).
Clonidine (10“  ^M-10“  ^M) also inhibited the initial component and 
potentiated the second component of the motor response to field 
stimulation (Fig. 8). TTX (3 x 10“  ^M) abolished both components of 
the biphasic response to field stimulation (Fig. 8).
ATP (10”3 M) inhibited both components of the biphasic motor 
response to field stimulation. Although the ability of NA (3 x 
10-5 )^ to induce a contraction was unaffected, ATP (10“  ^M) could no 
longer elicit a contractile response at a time when the field 
stimulation-evoked motor response was inhibited by ATP (10“  ^M)
(Fig. 9).
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FIGURE 5a. Typical biphasic contractions of the mouse vas deferens to 
field stimulation at 20 Hz starting at S and lasting for 5 sec.
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FIGURE 5b. Contractions of the mouse vas deferens to field 
stimulation (20 Hz, starting at S and lasting for 5 sec). 
Phentolamine (0, 10“  ^M) enhanced the initial component and inhibited 
the second component.
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FIGURE 6. Biphasic contractions of the mouse vas deferens to 
electrical field stimulation at 20 Hz, starting at S and lasting for 
5 sec. Morphine (10“  ^M) added between the first and second responses 
slightly reduced the initial component and potentiated the second 
component. When the concentration of morphine was increased from 
10”  ^M to 10-5 between the second and third responses, the initial 
component was further reduced and the second component further 
potentiated.
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FIGURE 7. Effects of morphine (10"^ M-10”  ^M) on biphasic motor 
responses of the vas deferens to field stimulation. The results 
are expressed as percentage changes from controls. The lower, open 
histograms show the dose-related inhibitory effects of morphine on the 
initial NANC component of the motor response. The upper, shaded 
histograms show the potentiating effect of morphine on the second 
noradrenergic component of the motor response. Naloxone (10”  ^ M) 
antagonised the effects of morphine (10“  ^M) on both phases of the 
motor response to field stimulation. Each column represents the 
mean (- S.E. mean) of 6 observations.
* 0.05>P>0.01, ** 0.01>P>0.001 for comparison with corresponding
controls.
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FIGURE 8. Effects of clonidine (10”  ^M-10”  ^M) on biphasic motor 
responses of the vas deferens to field stimulation. The results are 
expressed as percentage changes from controls. The lower, open 
histograms show the dose-related inhibitory effects of clonidine on the 
initial NANC component of the motor response. The upper, shaded 
histograms show the potentiating effect of clonidine on the second 
noradrenergic component of the motor response. Tetrodotoxin (TTX, 3 x 
10“  ^M) blocked both phases of the motor response to field stimulation. 
Each column represents the mean (- S.E. mean) of 7 observations.
* 0.05>P>0.01, ** 0.01>P>0.001 for comparison with corresponding
controls.
FIGURE 9. Contractions of the mouse vas deferens to field stimulation 
(20 Hz, starting at S and lasting for 5 sec.). Exogenous ATP (10“3 M) 
produced a small, short-lived contraction and NA (3 x 10”-* M) produced 
a more sustained contaction which was reversed by washing. ATP 
(10”3 M) inhibited the contractile response to field stimulation 
(20 Hz, starting at S and lasting for 5 sec.). In the absence of 
washing, ATP (10“3 M) produced a negligible response, but the 
contractile response to NA (3 x 10”-* M) was maintained. Following 
washing, field stimulation-induced responses were of similar magnitude 
to those obtained prior to drug addition.
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Reserpine pretreatment changed the nature of the contraction 
evoked by field stimulation, producing an inhibition of the second 
component of the biphasic motor response (Fig. 10).
6-OHDA pretreatment also changed the nature of the motor response 
to field stimulation. The typical biphasic response was converted to 
a monophasic contraction which was unaffected by phentolamine (10“  ^M) 
(Fig. 11).
Contractile responses to field stimulation in control vasa were 
abolished by TTX (10”  ^M, 3 x 10”  ^M), which had no effect on responses 
of tissues from 6-OHDA pretreated animals (Fig. 12).
Reserptnlsed
Control
ig
FIGURE 10. Contractions of the mouse vas deferens to field 
stimulation at 20 Hz, starting at S and lasting for 5 sec. Upper 
panel shows the inhibitory effect of reserpine pretreatment on the 
second component of the biphasic motor response to field stimulation. 
Lower panel shows typical biphasic contractile responses to field 
stimulation.
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FIGURE 11. Monophasic contractions to field stimulation (20 Hz, 
starting at S and lasting for 5 sec.) in vasa from 6-OHDA pretreated 
mice, showing the lack of effect of phentolamine (t), (10“  ^ M).
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FIGURE 12. Traces showing the inhibitory effects of TTX on responses 
of isolated mouse vasa to field stimulation and the lack of effect of 
TTX in vasa from 6-OHDA pretreated animals. Upper trace from a 
control vas to trains of 100 pulses, delivered at 20 Hz and 100 sec. 
intervals. TTX (§, 10”® M and • , 3 x 10~® M) produced dose-dependent 
inhibitions that were reversed with washing. Lower trace shows 
responses of a vas from a 6-OHDA pretreated mouse to trains of 100 
pulses at 20 Hz every 100 sec., on which TTX (f, 10“® H and I, 3 x 
10"® M) had no effect.
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PART II
EFFECTS OF ACUTE ARP CHRONIC DRUG ADMINISTRATION ON 
RESPONSES OF MOOSE ISOLATED VASA
Pretreatment with 6-OHDA increased the sensitivity of isolated 
vasa to NA. The supersensitivity was characterised by a large 
increase in the maximum response to NA (Fig. 13).
High concentrations of ATP, added exogenously to the bath, 
elicited contractile responses (Figs. 14, 15).
0Control n=14 
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FIGURE 13. Dose-response curves to NA in isolated vasa from control
(f f) an(i 6-OHDA pretreated (A. & ) mice. Each point is the
mean (- S.E. mean) of { 8 observations.
* 0.05>P>0.01i «** P<0.001.
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FIGURE 14. Dose-response curve showing the effect of ATP in vasa. 
Each point is the mean (- S.E. mean) of 4 observations.
% maxi mum
100
90-
70-
50-
30-
20-
10 -
Log ATP (M)
FIGURE 15. Dose ^-response curve showing the effects of ATP in vasa. 
Each point is the mean (- S.E. mean) of 4 observations.
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PART III
EFFECTS OF 6-OHDA PRETREATMENT AND ACPTELY ADMINISTERED DRUGS ON 
RESPONSES OF THE IN SITU VAS DEFERENS OF THE ANAESTHETISED RAT TO 
FTELD STIMULATION AND STIMULATION OF THE SPINAL MOTOR NERVES
Stimulation of the vas in situ, either via an electrode inserted 
into the spinal canal, or by field stimulation with local electrodes 
placed around the vas, produced biphasic responses similar to those 
produced by field stimulation in isolated vasa (Fig. 16).
In anaesthetised control rats, the shape of the response to in 
situ field stimulation was altered and the response to stimulation of 
the spinal outflows was inhibited by clonidine (500 jig/kg). These 
effects were antagonised by yohimbine (1 mg/kg) (Fig. 16). Control 
responses were abolished by TTX (T, 2 mg/kg) (Fig. 17).
6-OHDA pretreatment changed the nature of the motor response 
evoked either by nerve stimulation or by field stimulation. The small 
residual monophasic contraction, evoked by stimulation of the spinal 
motor outflows, was abolished by TTX (T, 2 mg/kg). The monophasic 
residual response evoked by in situ field stimulation was reduced, but 
not abolished, by TTX (T, 2 mg/kg) (Fig. 17).
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FIGURE 16. Contractile responses of the jLn situ vas deferens to 
electrical field stimulation and stimulation of spinal motor nerves in 
the anaesthetised rat.
FS: Field stimulation at different frequencies for the periods
indicated by the bars produced characteristic biphasic responses. 
Clonidine (500 pg/kg) altered the shape of the contractile response, 
slowing the rate of rise of the response and altering its biphasic 
nature, resulting in a more monophasic contraction. Yohimbine 
(1 mg/kg), antagonised the ability of clonidine to slow the rate of 
rise and the shape of the response and, in addition, enhanced both 
phases of the contraction above the size of the control response.
MS: In the same animal, the biphasic contractile response to
stimulation of the spinal motor nerves to the vas was inhibited by 
clonidine (500 i^g/kg) and this inhibition was also antagonised by 
yohimbine (1 mg/kg).
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FIGURE 17. Contractile responses of the in situ vas deferens to 
electrical field stimulation and to stimulation of the spinal motor 
nerves in an anaesthetised intact rat and in an anaesthetised, 6-OHDA 
pretreated rat. Electrical stimulation was applied at the frequencies 
shown and for the periods indicated by the bars.
The upper panel shows biphasic motor responses to in situ field 
stimulation (A) and stimulation of the spinal motor nerves (B) in the 
same control rat, abolished by 2 mg/kg TTX (T).
The lower panel shows small, monophasic responses to in situ field 
stimulation in a 6-OHDA pretreated rat (C). These responses were 
reduced but not abolished by 2 mg/kg TTX (T). In the same rat, spinal 
motor nerve stimulation produced a very small motor response that was 
abolished by 2 mg/kg TTX (T).
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PART IV
EFFECTS OF THYROXINE PBETREATMEWT ON PRE- AMD POST-SYNAPTIC 
RECEPTOR SENSITIVITY
Thyroxine (T^)-pretreatment increased serum free T^ levels (Fig. 
18). This change was accompanied by alterations in the sensitivity of 
the vas to agonists acting at both pre- and post-synaptic sites.
Tjj-pretreatment reduced the inhibition produced by morphine and 
clonidine, but had little effect on the maximum percentage inhibitions 
produced by these drugs (Figs. 19, 20, 21, 22).
Tjj-pretreatment also reduced the maximum contractile response to 
NA with no displacement of the NA dose-response curve (Figs. 23, 24).
Pretreatment with T^ reduced the maximum contractile response to 
carbachol and produced a rightward displacement of the carbachol dose- 
response curve (Figs. 25, 26).
Pretreatment with a combination of T^ + 6-OHDA similarly 
increased the maximum contractile response to carbachol in comparison 
to pretreatment with 6-OHDA alone (Fig. 27).
Combined pretreatment of T^ + 6-OHDA increased the maximum 
contractile response to NA to a greater extent than pretreatment with 
6-OHDA alone (Fig. 28).
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FIGURE 18. The unbound T^ levels in plasma, measured in pmol free 
Tjj/l, in both control and T^-pretreated mice. Each column represents 
the mean (- S.E. mean) of 8 observations. P<0.001.
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FIGURE 19. Dose-response curves showing inhibitory effects of
morphine in vasa from control (t •) and T^-pretreated ( O  Q)
mice, stimulated at 20 Hz for 0.5 msec. Each point is the mean 
(- S.E. mean) of { 8 observations. *** PC0.001.
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FIGURE 20. Dose ^-response curves showing effects of morphine in vasa
from control (•--- -#) and T^-pretreated (□ Q) mice, stimulated at
20 Hz for 0.5 msec. Each point is the mean (- S.E. mean) of ^  8 
observations.
Control n=12
Thyroxine n=8
FIGURE 21. Dose-response curves showing inhibitory effects of
clonidine in vasa from control (•----•) and T^-pretreated ( Q ----□)
mice, stimulated at 20 Hz for 0.5 msec. Each point is the mean 
(- S.E. mean) { 8 observations. *** P<0.001.
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FIGURE 22. Dose ^-response curves showing effects of clonidine in
vasa from control (•----1) and T^-pretreated ( Q  Q) mice,
stimulated at 20 Hz for 0.5 msec. Each point is the mean (- S.E. 
of { 8 observations.
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FIGURE 23. Dose-response curves showing effects of NA in vasa from
control (•----•) and T^-pretreated ( Q  Q) mice. Each point is the
mean (- S.E. mean) of { 8 observations.
* 0.05>P>0.01; •* 0.01>P>0.001.
Pe
rc
en
t 
ma
xi
mu
m
100-n
9 0 - Control n = 12
Thyroxine n = 8
7 0 -
6 0 -
5 0 -
30-
20 -
10-
6 57
Log NA(M)
FIGURE 2k, Dose ^-response curves showing effects of NA in vasa from
control (•--- -•) and T^-pretreated (□ ---- □) mice. Each point is the
mean (- S.E. mean) of  ^8 observations.
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FIGURE 25. Dose-response curves showing effects of carbachol in vasa
from control (•----1) and T^-pretreated ( Q — — Q) mice. Each point
is the mean (- S.E. mean) of { 8 observations.
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FIGURE 26. Dose ^-response curves showing effects of carbachol in
vasa from control (•— — t) and T^-pretreated (Q  □) mice. Each
point is the mean (- S.E. mean) of J: 8 observations.
* 0.05>P>0.01, •• 0.01>P>0.001, *** P<0.001.
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FIGURE 27. Dose-response curves to carbachol in isolated vasa from
control (0— — 0), 6-OHDA pretreated (t----•) and 6-OHDA + pretreated
(A A) mice. Responses to carbachol were potentiated in vasa
pretreated with 6-OHDA and a combination of 6-OHDA + T^ . The 
uppermost asterisks at 3 x 10“  ^M, 10“** M and 3 x 10“** M indicate 
significant changes resulting from 6-OHDA and 6-OHDA + pretreatments 
in comparison with controls. The uppermost asterisks at 10”2* M,
3 x 10“  ^M and 10“** M indicate significant changes resulting from a 
combination of 6-OHDA + T^ pretreatment in comparison with controls.
At these same concentrations, the lower asterisks indicate significant 
changes resulting from 6-OHDA pretreatment in comparison with controls. 
Each point is the mean (- S.E. mean) of 8 observations.
» 0.05>P>0.01, «* 0.01>P>0.001, *** P<0.001.
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FIGURE 28. Dose-response curves to NA in isolated vasa from control
(0— —0), 6-OHDA pretreated (•----• ) and 6-OHDA + pretreated
(A A) mice. Responses to NA were, enhanced in vasa from 6-OHDA
pretreated mice and were further potentiated in vasa from mice pretreated 
with a combination of 6-OHDA + T^ . Asterisks indicate significant 
changes resulting from 6-OHDA and 6-OHDA + pretreatments in 
comparison with controls. The asterisk at 10”  ^M indicates a 
significant difference between vasa from controls and from mice 
pretreated with a combination of 6-OHDA + T^ . The asterisk at 
10-5 M indicates a significant difference between vasa from 6-OHDA 
pretreated mice and mice pretreated with a combination of 6-OHDA + T^ . 
Each point is the mean (- S.E. mean) of  ^8 observations.
* 0.05>P>0.01, *** PC0.001.
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PART V
EFFECTS OF FTELT) STIMULATION ON THE OVERFLOW OF 3H ARP 
THE EFFECTS OF DRUGS ON THIS OVERFLOW
Electrical field stimulation of the vas increased the amount of 
radioactivity released into the Krebs solution in the organ bath.
Such increases coincided with the field stimulation-evoked 
contractions, after which further collection of Krebs solution between 
stimulations contained only low levels of radioactivity. Chromato­
graphic separation of (^H)-NA from its metabolites showed that field 
stimulation increased the overflow of (^H)-NA. Whereas only 34$ of 
the spontaneous ^H overflow was recovered as (^H)-NA, almost 80$ of 
the ^H radioactivity released into the bathing solution during field 
stimulation was (^H)-NA (Table I).
Table I. Percentage of (3H)-NA and its (3H)-metabolites in Krebs 
solution bathing isolated, field stimulated vasa deferentia.
Time
Before
During
(3H)-deaminated
(3H)-NA ($) (3H)-NMN ($) metabolites (%)
stimulation 34 ± 8 (5) 33 ± 6 (5) 30 ± 10 (5)
stimulation 77 - 8 (5) 16 ± 5 (5) 7 ± 3.5 (5)
mean percentages - S.E. mean (n)
deaminated metabolites : DOMA, DOPEG, MOPEG, VMA
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o
JH overflow was unaffected by treatment with a combination of 
tranylcypromine 10"*** M, desmethylimipramine 10“-* M and 17,3-oestradiol
_ C
10”3 M, which block respectively MAO and the neuronal and extraneuronal 
uptake of NA (Fig. 29). PBA (4 x 10“-* M), which, in addition to 
blocking these disposal mechanisms, also blocks presynaptic 
o^-adrenoceptors, potentiated overflow (Fig. 30).
Effect of 10 5M (tranylcypromine + DMI + 17/3 - 
oestradiol) on 5H overflow
FIGURE 29. Effect of tranylcypromine 10“5 M^+ desmethylimipramine 
10-5 ^ + ‘i7>p_oestradiol 10“5 M, on field stimulation-evoked overflow 
of in the vas deferens. The open histograms show successive 
control responses prior to drug addition. The shaded histogram shows 
the lack of effect of the combination of drugs to block monoamine 
oxidase (MAO) and the neuronal and extraneuronal uptake of NA in the 
same experiments. Each column represents the mean (- S.E. mean) of 6 
observations.
Ef fect of p h e n o x y b e n z a m i n e  on o v er flo w
***
4 x 1 0 " 5 M
FIGURE 30. Effect of phenoxybenzamine (4 x 10“5 M) on field 
stimulation-evoked overflow of in the vas deferens. The open 
histograms show successive control responses prior to drug addition.
The shaded histogram shows the potentiating effect of phenoxybenzamine 
(4 x 10“5 M) in the same experiments. Each column represents the mean 
(- S.E. mean) of 6 observations.
*** P<0.001 for comparison with control prior to drug addition.
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Morphine (10“  ^M-10“  ^M) increased the overflow of radioactivity 
from vasa of both T.O. (Fig. 31) and Porton (Fig. 32) mice and this 
effect was antagonised by naloxone (10“  ^ M) (Fig. 33). The ability of 
morphine to enhance overflow occurred in the presence of a 
combination of drugs which block MAO and the neuronal and extraneuronal 
uptake of NA (Fig. 34).
Clonidine (10“  ^M-10"*^  M) also increased the overflow of 
radioactivity from vasa of both T.O. (Fig. 35) and Porton (Fig. 36) 
mice. The ability of clonidine to increase overflow occurred in 
the presence of blocking drugs (Fig. 37).
Chromatographic separation of (^H)-NA from its metabolites showed 
that there was little change in the percentage of (^H)-NA released into 
the bathing solution during field stimulation in the presence of 
morphine or clonidine (Table II).
Effect of morphine on 5H overflow.
FIGURE 31. Effect of morphine (10“  ^ M-10”  ^M) on field stimulation- 
evoked overflow of in vasa from T.O. mice. The open histograms
shown successive control responses prior to drug addition. The 
succeeding 3 shaded histograms show the potentiating effect of morphine 
added in increasing concentrations (10"^ M-10”  ^M) in the same 
experiments. Each column represents the mean (- S.E. mean) of 6 
observations.
# 0.05>P>0.01, ** 0.01>P>0.001 for comparison with control prior to
drug addition.
Effect of Morphine on overflow
10"7M 10"6M 10"5M 3x10~6M 
TTX
FIGURE 32. Effect of morphine (1 CT7 M-10“  ^M) on field stimulation- 
evoked overflow of in vasa from Porton mice. The open histograms 
show successive control responses prior to drug addition. The 
succeeding 3 shaded histograms show the potentiating effect of morphine 
added in increasing concentrations (10”*^ M-10“  ^M) in the same 
experiments. Tetrodotoxin blocked field stimulation-evoked 
overflow. Each column represents the mean (- S.E. mean) of 6 
observations.
* 0.05>P>0.01, ** 0.01>P>0.001, *** P<0.001 for comparison with control
prior to drug addition.
Effect of Morphine and Naloxone on 3H overfl ow
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FIGURE 33. Effect of morphine (10”  ^M) on field stimulation-evoked 
overflow of in the vas deferens. The open histograms show 
successive control responses prior to drug addition. The succeeding 2 
stippled histograms show the potentiating effect of morphine (10“  ^M) 
in the same experiments. Thereafter, the addition of naloxone 
(10“  ^M) (stippled/striped histograms) antagonised the effect of 
morphine (10"^ M). Each column represents the mean (- S.E. mean) of 
6 observations.
*** P<0.001 for comparison with control prior to drug addition.
Effect of morphine on 3H overflow in the presence of 
10“5M (tranylcypromine/ 17-/3 oestradlol and DMI).
#**
10'7M 10"5M 10"5M
FIGURE 34. Effect of morphine (10”*^ M-10“5 M) on field stimulation- 
induced overflow of in the vas deferens, in the presence of a 
combination of drugs (tranylcypromine 10“ 5 M, desmethylimipramine 
10-5 17-|3-oestradiol 10“5 M) to block MAO and the neuronal and
extraneuronal uptake of NA. The open histograms show successive 
control responses prior to drug addition. The succeeding 3 shaded 
histograms show the potentiating effect of morphine added in increasing 
concentrations (10“*^ M-10“5 M) in the same experiments. Each column 
represents the mean (- S.E. mean) of 8 observations.
** 0.01>P>0.001, *** P<0.001 for comparison with control prior to drug 
addition.
Effect of clonidine on 3H overflow.
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FIGURE 35. Effect of clonidine (10“9 M-IO"17 M) on field stimulation- 
evoked overflow of in vasa from T.O., mice. The open histograms 
show succesive control responses prior to drug addition. The 
succeeding 3 shaded histograms show the potentiating effect of 
clonidine added in increasing concentrations (10~^ M-IO"17 M) in the 
same experiments. Each column represents the mean (- S.E. mean) of 6 
observations.
* 0.05>P>0.01, ** 0.01 >P>0.001, *** P<0.001 for comparison with control 
prior to drug addition.
Effect of Clonidine on 3H overflow
FIGURE 36. Effect of clonidine (10-9 M-10“  ^M) on field stimulation- 
evoked overflow of in vasa from Porton mice. The open histograms 
show successive control responses prior to drug addition. The 
succeeding 3 shaded histograms show the potentiating effect of 
clonidine added in increasing concentrations (10“  ^M-10”'7 M) in the 
same experiments. Tetrodotoxin (TTX, 3 x 10“8 M) blocked field 
stimulation-evoked overflow. Each column represents the mean 
(- S.E. mean) of 4 observations.
** 0.01>P>0.001, *** PC0.001 for comparison with control prior to drug 
addition.
Effect of clonidine on overflow/ in the presence of 
10_!?M (tranylcypromine/ 17-/3 oestradlol and DMI)
**
4-1 T
10’9M 10'8M 10"7m
FIGURE 37. Effect of clonidine (10“9 M-KT*7 M) on field stimulation- 
induced overflow of in the vas deferens, in the presence of a 
combination of drugs (tranylcypromine 10“5 M, desmethylimipramine 
10"5 M, 17-P-oestradiol 10“5 m ) to block monomaine oxidase (MAO) and 
the neuronal and extraneuronal uptake of NA. The open histograms show 
successive control responses prior to drug addition. The succeeding 3 
shaded histograms show the potentiating effect of clonidine added in 
increasing concentrations (10“9 M-10“  ^M) in the same experiments.
Each column represents the mean (- S.E. mean) of 6 observations.
* 0.05>P>0.01, ** 0.01>P>0.001 for comparison with control prior to
drug addition.
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Like clonidine and morphine, yohimbine (10~® M, 10""^  M) enhanced 
the overflow of and the potentiation was similar in the absence 
and presence of tranylcypromine (10“  ^M), desmethylimipramine (10~^ M) 
and 17,0-oestradiol (10“5 M) (Fig. 38).
TTX (3 x 10"^ M) reduced field stimulation-induced increases in 
radioactive overflow to basal levels (Figs. 32, 36).
N"\IO
<D
CO
CD
CD
CDczo
o
CD
Effect of yohimbine on \  overflow in the absence 
and presence of 10~®M (tranylcypromine +DMI+17, 
p -oestradlol).
5 -
3 -
2 -
I i
10_8M io‘7m
FIGURE 38. Effect of yohimbine (10”*® M, 10" 7 M) in the absence and 
presence of tranylcypromine 10"® M, + desmethylimipramine 10"® M + 
17,P-oestradiol 10"® M, on field stimulation-evoked overflow of in 
the vas deferens. The 3 open histograms show successive control 
responses prior to drug addition. The successive 2 vertical striped 
histograms show the significant potentiating effect of yohimbine 
(10"® M, 10"7 the same experiments. The 3 stippled histograms
show successive control responses prior to drug addition. The 
successive 2 vertical striped/stippled histograms show the significant 
potentiating effect of a combination of yohimbine (10"® M, 10"7 M) + 
tranylcypromine 10"® M, + desmethylimipramine 10"® M + 17,3-oestradiol 
10"® M in the same experiments. Each column represents the mean 
(- S.E. mean) of 4 observations.
* 0.05 >P>0.01 for comparison with control prior to drug addition.
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Neither morphine (10"’^  M-10“  ^M) nor clonidine (10“  ^M-10"^ M) 
produced any significant enhancement of overflow in T^-pretreated 
mice (Figs. 39, 40).
In the presence of PBA (4 x 10"^ M), overflow was increased 
significantly in mice pretreated with (Fig. 41).
Effect of Morphine on overflow in control and
T/j-treated animals
kill T/j-treated
10“7m 10-6M 10"5M
FIGURE 39. Effect of morphine (10“  ^M-10"^ M) on field stimulation- 
evoked overflow of in vasa from control and T^-pretreated animals. 
The 3 open histograms show successive control responses prior to drug 
addition. The 3 stippled histograms show successive responses in 
tissues from T^-pretreated animal prior to drug addition. The 
succeeding vertical striped and vertical striped/stippled histograms 
show the effect of morphine added in increasing concentrations 
(10~^ M-10“  ^M) in, respectively, tissues from control and T^- 
pretreated animals, in the same experiments. Each column represents 
the mean (- S.E. mean) of 6 observations.
* 0.05>P>0.01, ** 0.01 >P>0.001 for comparison with control prior to
drug addition.
Effect of Clonidine on 5H overflow In control and
T^-treated animals
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FIGURE *10. Effect of clonidine (10-9 M) on field stimulation-
evoked overflow of in vasa from control and T^-pretreated animals. 
The 3 open histograms show succesive control responses prior to drug 
addition. The 3 stippled histograms show successive responses in 
tissues from T^-pretreated animals prior to drug addition. The 
succeeding vertical striped and vertical striped/stippled histograms 
show the effect of clonidine added in increasing concentrations 
(10“9 M-10”  ^ M) in, respectively, tissues from control and Tjp 
pretreated animals in the same experiments. Each column represents 
the mean (- S.E. mean) of 6 observations.
# 0.05>P>0.01, f* 0.01>P>0.001, *** PC0.001 for comparison with control 
prior to drug addition.
Effect of p h e n o xybenza mine on 5H overflow in 
control and T^-treated animals.
* * *
55-1
treated
4x10~5M
FIGURE 41. Effect of phenoxybenzamine (4 x 10“-’ M) on field 
stimulation-evoked overflow of in vasa from control and T^- 
pretreated animals. The 3 open histograms show successive control 
responses prior to drug addition. The diagonal striped histograms 
show successive responses in tissues from T^-pretreated animals prior 
to drug addition. The succeeding vertical striped and 
vertical/diagonal striped histograms show the potentiating effect of 
phenoxybenzamine (4 x 10"^ M) in, respectively, tissues from control 
and T^-pretreated animals. Each column represents the mean (- S.E. 
mean) of 6 observations.
* 0.05>P>0.01, *** P<0.001 for comparison with control prior to drug 
addition.
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PART VI
EFFECT OF VARYING THE STIMULATION PARAMETERS ON THE OVERFLOW OF 3H
The effect of altering the stimulation parameters was investigated 
on the overflow of ^H.
Successive stimulations at a constant frequency (20 Hz) for a 
fixed number of pulses (100) caused a reduction in the overflow of H^, 
which levelled off after the 4th stimulation (Fig. 42).
Keeping the number of pulses constant at 100, but increasing the 
frequency of stimulation throughout the experiment, commencing with 
stimulation at 1 Hz for a period of 100 sec. and ending with stimulation 
at 20 Hz for a period of 5 sec., caused a reduction in ^H overflow 
throughout the course of the experiment (Fig. 43).
If the experiment was carried out in the reverse order, that is, if the 
frequency of stimulation was decreased throughout the experiment, 
commencing with stimulation at a frequency of 20 Hz for a period of 5 
sec. and ending with stimulation at a frequency of 1 Hz for a period of 
100 sec., the amount of radioactivity released was enhanced (Fig. 44).
A similar pattern was obtained if' vasa were stimulated 3 times at 
each frequency and the mean ^H overflow was calculated (Figs. 45, 46).
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Effect of 5 stimulations on 5H overflow
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FIGURE 42. Effect of 5 consecutive stimulations at a frequency of 
20 Hz for a period of 5 sec. Each column represents the mean (- S. 
mean) of 24 stimulations.
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FIGURE JJ3. Frequency response relationship for a constant number of 
pulses (100) at increasing frequencies of stimulation from 1 Hz to 
20 Hz. Each column represents the mean (i S.E. mean) of 4 
observations.
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FIGURE MM. Frequency response relationship for a constant number of 
pulses (100) at decreasing frequencies of stimulation from 20 Hz to 
1 Hz. Each column represents the mean (* S.E. mean) of 6 
observations.
Frequency response relationship; mean of 3
stimulations at each frequency
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FIGURE 45. Frequency response relationship for a constant number of 
pulses (100) at increasing frequencies of stimulation from 1 Hz to 
20 Hz. In each experiment tissues were stimulated 3 times and the 
mean response was calculated. Each column represents the mean (- S.E. 
mean) of 4 separate experiments.
Frequency response relationship; mean of 3
stimulations at each frequency
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FIGURE 46. Frequency response relationship for a constant number of 
pulses (100) at decreasing frequencies of stimulation from 20 Hz to 
1 Hz. In each experiment, tissues were stimulated 3 times and the 
mean response was calculated. Each column represents the mean (i S.E. 
mean) of 4 separate experiments.
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Maintaining a constant time of 100 sec. but increasing the 
frequency of stimulation throughout the experiment from 1 to 20 Hz, 
resulted in an enhanced overflow of (Fig. 47). If* the experiment 
commenced with stimulation at a frequency of 20 Hz and ended with 
stimulation at a frequency of 1 Hz, the overflow of ^H was seen to 
diminish throughout the experiment (Fig. 48).
In the presence of PBA (4 x 10“-* M), the overflow of ^H at 
decreasing frequencies of stimulation, starting at 20 Hz for a period 
of 5 sec. and ending with stimulation at 1 Hz for 100 sec., was 
enhanced (Fig. 49).
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FIGURE 47. Frequency response relationship at increasing frequenc 
of stimulation from 1 Hz to 20 Hz for a constant time of 100 sec. 
Each column represents the mean (i S.E. mean) of 4 observations.
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FIGURE 48. Frequency response relationship at decreasing frequencies 
of stimulation from 20 Hz to 1 HZ for a constant time of 100 sec.
Each column represents the mean (- S.E. mean) of 4 observations.
Frequency response relationship in the absence 
and presence of Phenoxybenzamine ( 4 x 1 0 “^M)
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FIGURE 49. Frequency response relationship for a constant number of 
pulses (100) at decreasing frequencies of stimulation from 20 Hz to 
1 Hz in the absence (lower section of column) and presence (whole 
column) of phenoxybenzamine (4 x 10"5 M). Each column represents the 
mean (- S.E. mean) of 6 observations.
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PART VII
EFFECT OF FTKT.D STIMULATION AND AGOHISTS OH THE FORMATION OF T32Pl-PA
PI hydrolysis in the mouse vas deferens was monitored by the 
increased formation of [^^P]-PA in vasa preincubated with [^2P]- 
orthophosphate (Fig. 50).
NA M) increased the formation of [^^P]-PA in vasa
prelabelled with [^2P]-orthophosphate. This effect of NA was 
antagonised by prazosin (10-  ^ M) (Fig. 51). Neither ATP (10”  ^ M), nor 
a,p-MeATP (10“  ^M), altered the synthesis of [^2P]-PA (Fig. 51).
Electrical field stimulation increased the formation of [^2P]-PA 
and this response was antagonised by prazosin (10"^ M) and by TTX 
(10“6M) (Fig. 52).
fi Q
Neither morphine (10 M) nor clonidine (10 M) had any effect on 
the basal levels of [^2P]-PA formation nor on the ability of NA to 
enhance [^2P]-PA formation (Fig. 53).
Morphine (10”  ^M, 10“  ^M) potentiated the field stimulation- 
induced increase in [^2P]-PA formation and this effect was antagonised 
by naloxone (10“^M) (Fig. 54).
Clonidine (10“® M, 10“  ^M) potentiated the field stimulation- 
induced increase in [^2P]-PA formation in a dose-dependent manner 
(Fig. 55).
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FIGURE 50. Outline of inositol lipid metabolism. The key event is 
the hydrolysis of phosphatidylinositol 4,5-bisphosphate (Ptd.lns 
4,5 P2) to give diacylglycerol (DG) and inositol 1,4,5-trisphosphate 
(Ins 1,4,5 Pg)» both of which function as second messengers. A DG 
kinase converts DG to phosphatidic acid (PA) which is increased when 
the PI cycle is activated.
PA f o r m a t i o n  - %
c h a n g e  fr om co n t r o l
+90—j 
+80- 
+ 7 0 -  
+ 6 0 -  
+ 5 0 -  
+ 4 0 -  
+ 5 0 -
+ 20-
+ 1 0 -
0-
- 10 -
u p
NA NA ( 10'5 M) A T P  a,/3 MeATP 
(10‘ 5 M) p r a z .< i o _ 6 M) (10' 3m) (10 5 M)
FIGURE 51. Effect of NA, NA + prazosin, ATP and a,|3-MeATP on the 
formation of [^2P]-PA in the vas deferens. NA (10”  ^M, shaded 
histogram) increased PA formation and this effect was antagonised by 
prazosin (10“  ^M, stippled histogram). Neither ATP (10”  ^m, diagonal 
striped histogram) nor a,0-MeATP (10"^ M, vertical striped histogram) 
had any effect on the formation of PA. Each column represents the
mean (- S.E. mean) of 4 observations.
« 0.05>P>0.01.
PA formation - % 
change from control 
+80-,
+ 7 0 -  
+ 6 0 -  
+ 5 0 -  
+ 4 0 -  
+ 3 0 -  
+ 2 0 -  
+ 10-  
0
- 10 -
- 20-
F.S. F . S . +  F . S . +
Praz (10‘6 M) TTX (10~5 M)
FIGURE 52. Effect of field stimulation, field stimulation + prazosin 
and field stimulation + TTX on the formation of [^2P]-PA in the vas 
deferens. Field stimulation (shaded histogram) increased PA formation 
and this effect was antagonised by prazosin (10"^ M, stippled 
histogram), and by TTX (10”  ^M, diagonal striped histogram). The 1st 
column represents the mean (- S.E. mean) of 12 observations, the 2nd 
and 3rd columns represent the mean (- S.E. mean) of 4 observations.
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FIGURE 53. Effect of NA, morphine + NA, clonidine + NA, morphine and 
clonidine on the formation of [^2P]-PA in the vas deferens. NA 
(10“5 M, shaded histogram) increased PA formation and this enhancement 
was not potentiated any further by morphine (10“8 M, stippled 
histogram) or clonidine (10“  ^M, diagonal striped histogram). Neither 
morphine (10“8 M, vertical striped histogram) nor clonidine (10“8 M, 
open histogram) had any effect directly on PA formation. Each column 
represents the mean (- S.E. mean) of 4 observations.
• 0.05>P>0.01.
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FIGURE 54. Effect of field stimulation, field stimulation + morphine 
and field stimulation + morphine + naloxone on the formation of [^2P]- 
PA in the vas deferens. Field stimulation (shaded histogram)
increased PA formation. This increase was potentiated by morphine
(10“  ^M, diagonal striped histogram; 10”2* M, stippled histogram). In 
the presence of naloxone (10~8 M, vertical striped histogram) the 
addition of morphine did not result in any enhancement of the field 
stimulation-induced increase in PA formation. The 1st column 
represents the mean (- S.E. mean) of 12 observations, the remaining 3 
columns represent the mean (- S.E. mean) of 4 observations.
«** PC0.001.
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FIGURE 55. Effect of field stimulation and field stimulation + 
clonidine on the formation of [^2]-pA in the vas deferens. Field 
stimulation (shaded histogram) increased PA formation. This increase 
was potentiated in a dose-related manner by clonidine (10~® M, stippled 
histogram; 10"^ H, diagonal striped histogram). The 1st column 
represents the mean (t S.E. mean) of 12 observations, the 2nd and 3rd 
columns represent the mean (t S.E. mean) of 4 observations.
* 0.05>P>0.01, P<0,Q01.
D I S C U S S I O N
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This study has answered some of the questions posed in the 
introduction, but has raised others that may be more difficult to 
answer. It is clear that field stimulation-induced responses of the 
mouse vas deferens are biphasic, confirming observations obtained in 
vasa from other species (Ambache et al.. 1972; Blakeley et_ ai.. 1981; 
Fedan e_t al.. 1981; Brown ejb a_L, 1983; Sneddon et_ q \_., 1984). 
Evidence obtained in this and other studies indicates that, whereas the 
second component of the biphasic response to field stimulation is 
adrenergic, the initial component is neither adrenergic nor cholinergic 
(NANC). Despite the general acceptance of the existence of an IAIC 
transmitter that mediates the initial component of the biphasic 
response in vasa from several species, there remains a possibility that 
this response could arise from neurally-released NA acting on 
adrenoceptors that differ from the more familiar adrenoceptors.
Results from experiments carried out on vascular smooth muscle 
have led to the suggestion that two types of excitatory receptor exist 
for NA (Hirst & Neild, 1980; 1984). When activated, one type
produced a response that was not associated with any change in the 
membrane potential and could be abolished by the a-j-adrenoceptor 
antagonist prazosin. The other type of receptor was associated with a 
depolarisation and was unaffected by prazosin. It was proposed that 
this response resulted from the interaction of NA with an adrenoceptor 
which differed from the classical a-adrenoceptor and it was named the 
y receptor (Hirst & Neild, 1980; 1984). These observations obtained
from arteriolar smooth muscle were thought to provide a possible 
explanation for the paradoxical failure of a-adrenoceptor antagonists 
to block transmission in the vas deferens. One experimental obstacle 
which prevents acceptance of NA as the sole transmitter in this tissue 
is the survival of the initial component after reserpine pretreatment
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(Ambache & Zar, 1971; Swedin, 1971; Booth e£. &1., 1978; Sneddon & 
Burnstock, 1984; Stjarne & Sstrand, 1985; Kirkpatrick & Burnstock, 
1987). This study confirmed that reserpine pretreatment inhibited the 
second component but did not affect the initial component of the motor 
response to field stimulation in isolated vasa.
Other workers have presented evidence which supports an 
alternative hypothesis, namely that ATP, released as a co-transmitter 
with NA from sympathetic nerves in the vas deferens, mediates the 
initial contractile response (French & Scott, 1983; Meldrum & 
Burnstock, 1983; Sneddon & Burnstock, 1984; Sneddon & Westfall,
1984). Despite the extensive experimental results in support of co­
release of ATP and NA, this explanation of transmission in the vas 
deferens has not been accepted without some reservations (Allcorn et. 
al.. 1986). However, the bulk of evidence favours the motor response 
being explained by the co-transmission hypothesis.
One question that has remained in dispute is whether or not the 
co-transmitters are contained in a single nerve or in separate nerves. 
Proponents of the separate nerve hypothesis claim that a residual 
response surviving 6-OHDA pretreatment is due to separate NANC nerves 
(Booth ai.., 1978). However, the effects of drugs which are known 
to preferentially inhibit the initial component of the motor response 
were not investigated in these studies, nor were the effects of 
tetrodotoxin (TTX) examined in order to confirm that the residual 
contraction was neurally-mediated.
This study re-examined the effect of pretreating animals with 
6-OHDA to determine whether or not any response survived this treatment 
and, if such a response remained, to investigate if it was abolished by 
TTX and affected by drugs which preferentially inhibited the initial 
component of the biphasic response of control vasa to field
stimulation. In addition to examining the effects of drugs on 
responses of vasa from 6-OHDA pretreated animals in vitro, a novel 
preparation was introduced, where the inherent problem associated 
with field stimulation, namely the possibility of direct stimulation of 
the smooth muscle, would be absent. The effects of stimulating the 
spinal motor outflows to the vas deferens of anaesthetised control and 
6-OHDA pretreated rats were examined. By this means, stimulation of 
the nerves at their point of origin in the spinal canal permitted the 
effects of 6-OHDA pretreatment to be examined in a situation where 
direct stimulation of the smooth muscle could not occur. In addition, 
the responses of vasa to jjQ. situ field stimulation were investigated in 
these animals. Thus, it was possible to examine the effects of drugs 
on responses resulting from stimulation of the spinal motor nerves to 
the vas deferens and responses to in situ field stimulation of vasa in 
the same preparation.
Results obtained in this study confirmed that in isolated tissues 
a residual response survived pretreatment with 6-OHDA. However, this 
response was unaffected by clonidine or opiates, which preferentially 
inhibited the initial component of the biphasic response to field 
stimulation in control vasa. TTX, which normally abolished all 
responses to field stimulation in vasa from control animals, did not 
affect the residual response that survived pretreatment with 6-OHDA. 
This observation indicated that the residual response was not neurally- 
mediated but possibly resulted from direct stimulation of the smooth 
muscle, which was found to be supersensitive to NA. Thus, 6-OHDA 
pretreatment may not only have made the vas supersensitive to NA, but 
may also have lowered the threshold for direct stimulation of the 
smooth muscle. To distinguish a situation where the smooth muscle 
could be directly stimulated from one where this would not be possible,
the effects of clonidine, opiates and TTX were examined in 
anaesthetised animals. In controls, stimulation of the vasa, both by 
in situ field stimulation and via stimulation of the spinal motor 
nerves, produced biphasic responses, similar to those resulting from 
field stimulation In vitro. The initial component of the biphasic 
responses was inhibited by opiates and clonidine and the entire 
response was abolished by TTX. In 6-OHDA-pretreated animals, a 
residual response to in situ field stimulation persisted and, as in the 
isolated vas, TTX did not abolish this response. Thus, this residual 
contraction may have resulted from direct stimulation of the smooth 
muscle during in situ field stimulation, where the electrodes were 
closely applied to the vas. It could be argued that the residual 
response to field stimulation in 6-OHDA-pretreated animals was not due 
to direct stimulation of the smooth muscle but to a resistance to TTX 
and there is evidence that high intensity electrical stimulation of the 
vas deferens releases NA even in the presence of TTX (Illes et. al..
198-4). Such an explanation seems unlikely, since it would require 
that responses to field stimulation in vasa from 6-OHDA-pretreated 
animals were TTX resistant but those from controls were not. When the 
spinal motor nerves to the vas were stimulated in these 6-OHDA- 
pretreated animals, a small contraction was obtained. However, this 
residual response, unlike the responses occurring as a result of field 
stimulation both in vitro and in situ, was abolished by TTX, suggesting 
that it was perhaps mediated by a few adrenergic fibres that survived 
pretreatment with 6-OHDA.
This study demonstrated that the field stimulation-induced 
contractile response surviving 6-OHDA-pretreatment resulted from direct 
stimulation of the smooth muscle which was supersensitive. The 
results are, therefore, in agreement with Fedan et. al. (1981) and
French & Scott (1983), in favour of the existence of the transmitters 
in the vas deferens being in a single nerve, which is destroyed by 
6-OHDA, resulting in the removal of any nerve-mediated response.
A biphasic mechanical response is indicative of more than one 
transmitter being released by field stimulation. However, this study 
confirmed that the two components of the biphasic response to field 
stimulation in the mouse vas deferens could be preferentially affected 
by drugs, providing further evidence for the release of more than one 
transmitter. a-Adrenoceptor antagonists such as phentolamine 
inhibited the second component of the motor response and both morphine 
and clonidine inhibited the initial component. However, surprisingly, 
at a time when morphine and clonidine were inhibiting the first 
component of the biphasic motor response, the second component was 
enhanced. This observation suggested that, not only was more than one 
transmitter released on field stimulation, but that the transmitters 
may be involved in a presynaptic feedback regulation. The results 
from the experiments designed to ascertain whether or not the 
transmitters in the vas are contained in a single nerve or in separate 
nerves, suggested that they are contained within a single nerve. 
Obviously this would require a more complex explanation for a possible 
cross-regulation than had the transmitters been released from separate 
nerves. However, it is unsatisfactory to examine the effects of drugs 
such as morphine and clonidine, which are generally thought to act 
presynaptically to inhibit the release of transmitter (Hughes et. al.. 
1975a; Gillan .§1 .al.., 1979), by monitoring postsynaptic events.
Although the mouse vas deferens has been used to study adrenergic 
mechanisms by assaying the effects of compounds which act 
prejunctionally to inhibit transmitter release, a more direct method of 
examining the sensitivity of presynaptic receptors would be to measure
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the output of transmitter. This eliminates the involvement of 
postsynaptic events in the analysis of the results.
Since NA is widely believed to be one of the transmitters in the 
vas deferens, part of this study investigated the effects of a variety 
of drugs on the release of NA from vasa preincubated with (^H)-NA.
Field stimulation of the vas increased the amounts of radioactivity 
released into the bathing solution, and these increases coincided with 
the field stimulation-evoked contractions. TTX abolished (^H)-NA 
overflow, indicating that it was neurally mediated.
The inactivation of neurally-released NA is carried out by 
neuronal uptake, which reduces the concentration of released transmitter 
in the synaptic cleft (Langer, 1977). Thus, neuronal uptake of NA can 
regulate the amount of transmitter which is available to activate the 
presynaptic a-adrenoceptors (Langer, 1974). This study has shown that 
a combination of tranylcypromine, desmethylimipramine and 17,3- 
oestradiol which block, respectively, monoamine oxidase (MAO) and the 
neuronal and extraneuronal uptake of NA, did not produce a significant 
increase in the overflow of (^H)-NA. This supports the view that 
blockade of neuronal uptake enhances the amount of transmitter 
available to activate presynaptic a-adrenoceptors, leading to enhanced 
feedback inhibition (Langer, 1977). However, combination of the drugs 
which block MAO, Uptake ,j and Uptake2 with the a-adrenoceptor antagonist 
yohimbine, increased (^H)-NA overflow to the same extent as yohimbine 
alone. If tranylcypromine, desmethylimipramine and 17,3-oestradiol 
enhanced the amount of NA in the synaptic cleft leading to a greater 
feedback inhibition via a-adrenoceptors, the combination of these drugs 
with yohimbine would be expected to have resulted in a greater overflow 
of (^H)-NA when compared to the overflow obtained in the presence of 
yohimbine alone. This result was not obtained, thus the explanation
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of the increased transmitter in the synaptic cleft arising from 
blockade of uptake, leading to enhanced activation of presynaptic 
a-adrenceptors, is inadequate for the mouse vas deferens. Considering 
the dense adrenergic innervation of this tissue, these paradoxical 
results are in agreement with other workers, who found that inhibition 
of the uptake mechanisms with highly-selective drugs produced little 
enhancement of NA overflow (Farnebo & Malmfors, 1971).
Phenoxybenzamine (PBA), which, in addition to blocking MAO and the 
neuronal and extraneuronal uptake of NA, also blocks presynaptic 
-adrenoceptors (Gillespie, 1980), significantly potentiated (^H)-NA 
overflow, confirming that these receptors are involved in the 
regulation of NA release through a negative feedback mechanism (Farnebo 
& Hamberger, 1971; Kirpekar & Puig, 1971; Langer et 1^., 1971;
Starke, 1971).
The surprising observation that morphine and clonidine inhibited 
the initial NANC component of the motor response to field stimulation 
but potentiated the second component, was corroborated in the overflow 
experiments, where both of these drugs were found to increase the 
overflow of (^H)-NA. It seems likely that the ability of morphine and 
clonidine to potentiate (^H)-NA overflow was receptor-mediated, since 
it occurred at low concentrations and was dose-related. The ability 
of morphine to increase (^H)-NA overflow was antagonised by naloxone.
It appears that the ability of these drugs to increase (^H)-NA overflow 
is due to a presynaptic action on release rather than on the removal 
mechanisms for NA, since the ability of both clonidine and morphine to 
enhance (^H)-NA overflow persisted in the presence of tranylcypromine, 
desmethylimipramine and 17> (3-oestradiol.
Although many studies have shown that the two phases of the field 
stimulation-induced motor response of the vas can be differentially
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affected by drugs (e.g. Sneddon e£ si.., 1984), the observation that
morphine and clonidine, which are generally believed to act 
presynaptically to inhibit the release of transmitter (Hughes e£. al.r 
1975a; Gillan e£ si., 1979), actually enhanced the overflow of 
transmitter in this study was surprising.
Several studies have used inhibition of field stimulation-induced 
motor responses of the mouse vas deferens to assay opiate activity 
(Henderson et si-> 1972; Hughes si Si., 1975a; Henderson & Hughes, 
1976). However, there are several ways in which the experiments of 
Henderson and Hughes differed from the present investigation; for 
example, many pairs of vasa were stimulated in order to obtain a 
measurable output of NA and experiments wherein the stimulated output 
declined by more than 10$ per stimulus train were rejected, so that 
perhaps an unrepresentative sample was chosen. The opiate receptor 
antagonist, naloxone, was present for 20 minutes but the results were 
apparently not corrected for the background release of radioactivity 
over this period, perhaps giving a false impression of a reversal of 
inhibition due to a large basal level. Moreover, the stimulation 
parameters used to investigate the inhibitory effects of morphine on 
contractions elicited by field stimulation differed from those used to 
release and measure NA. Contractile responses were evoked by short 
trains of pulses at 0.1-1.0 Hz and these were readily blocked by 
opiates. However, much longer trains of pulses at 0.5, 1.5 or 15 Hz 
were used in studies to measure NA output (Henderson & Hughes, 1976). 
In one study the same stimulation parameters were used to evoke both 
contractions and NA output (Henderson al., 1972) although results 
from only one experiment were shown. It is interesting that morphine 
was shown to have no effect on field stimulation-induced contractions 
at a frequency of 10 Hz, since morphine can inhibit contractile
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responses by up to 75$ at this, or a higher frequency. Such 
frequencies of stimulation are routinely used to assess the sensitivity 
of opiate receptors in tissues from both untreated and drug-pretreated 
animals (McCulloch & Pollock, 1985; Forsyth et. jd., 1987).
The results of this study are in agreement with those of Stjarne 
(1975a), who reported that clonidine "surprisingly” potentiated motor 
responses and (^H)-NA overflow in the field stimulated isolated guinea- 
pig vas deferens. Before considering a possible explanation of the 
results, it is worth noting that although the adrenergic innervation of 
the vas deferens had been questioned (Ambache & Zar, 1971), Hughes et 
al. considered that "the motor innervation of the vas deferens is 
adrenergic and that morphine acts by inhibiting the release of NA from 
the motor nerve terminals". Since morphine inhibited contractions, 
and these contractions were considered to be adrenergic, it is 
difficult to envisage any explanation of the results other than 
morphine acting presynaptically to inhibit the release of the motor 
transmitter NA.
An important question arising from the results obtained in this 
study is, how could morphine and clonidine inhibit the release of the 
NANC transmitter, as indicated by the reduced size of the initial 
component, whilst potentiating the release of NA?
Several experimental observations suggest that there are at least 
2 motor transmitters in the vas deferens, NA and an NANC transmitter 
that may be ATP (Fedan e£ &1.» 1981; Meldrum & Burnstock, 1983;
Sneddon & Westfall, 198-4). It has been proposed that ATP, released as 
a co-transmitter together with NA, activates postjunctional 
purinoceptors which are of the P2 sub-type (Burnstock, 1986). 
Neurally-released ATP is thought to act on postjunctional 
P2-purinoceptors to produce excitatory junction potentials (ejps),
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which are the underlying mechanism producing the initial, phasic 
component of the field stimulation-induced mechanical response (Sneddon 
et nXv 1982; Burnstock & Sneddon, 1984; Sneddon & Westfall, 1984). 
After its release and activation of postsynaptic receptors, ATP is 
rapidly broken down to adenosine which can act prejunctionally on P^- 
purinoceptors (De Mey .§£. aX., 1979; Moody & Burnstock, 1982;
Burnstock, 1986) to regulate transmitter release (Sneddon et $1., 1984; 
Burnstock, 1986).
Yohimbine enhanced the amplitude of ejps (Illes & Starke, 1983) 
and potentiated both phases of the contractile response to field 
stimulation (Stjarne & Xstrand, 1985). These effects of yohimbine 
were absent when the NA stores were depleted with reserpine, which 
reduced the concentration of NA below the threshold necessary for 
activation of prejunctional a^-adrenoceptors (Illes & Starke, 1983; 
Stjarne & Xstrand, 1985). These observations suggest that yohimbine 
interrupts an endogenous feedback mechanism on transmitter release.
This study confirmed that yohimbine enhanced field stimulation-induced 
biphasic motor responses and (^H)-NA overflow in the mouse vas 
deferens, providing direct evidence that neurally-released NA acts on 
prejunctional a^-adrenoceptors to inhibit further NA release. This 
study also provided indirect evidence that NA may also inhibit release 
of the transmitter mediating the initial component of the contractile 
response, since yohimbine enhanced the amplitude of the initial component 
of the motor response.
It is possible that activation of prejunctional P^-purinoceptors 
by a metabolite of the putative transmitter, ATP, leads to a parallel 
autoinhibition and neuromodulation. Interruption of such a feedback 
system would provide one possible explanation of the results obtained 
with morphine and clonidine, since introducing these drugs into such a
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complicated system would be expected to produce complex effects. It 
is possible that morphine and clonidine inhibit the release of ATP. 
This action would lead to less feedback inhibition via prejunctional 
P^-purinoceptors and, consequently, result in an enhanced release of 
NA.
This study set out to examine this hypothesis in two ways.
Firstly, it sought to determine indirectly if, indeed, ATP or its 
metabolites were involved in a feedback modulation of transmitter 
release, by examining the effects of ATP on field stimulation-induced 
motor responses. Secondly, it examined the effects of morphine and 
clonidine directly on the release of in vasa preincubated with (^ H)- 
adenosine.
The results from experiments investigating the effects of ATP on 
field stimulation-induced biphasic motor responses were consistent with 
the hypothesis that a metabolite of ATP, possibly adenosine, acts on 
prejunctional P^-purinoceptors to inhibit transmitter release. Both 
components of the motor response were inhibited in the presence of ATP, 
suggesting that activation of prejunctional P^-purinoceptors leads to 
inhibition of the release of both ATP and NA. Although the response 
to exogenous NA was not inhibited in the presence of ATP, at a time 
when the field stimulation-induced motor response was reduced, the 
ability of the tissue to respond to exogenous ATP was inhibited. This 
suggests that the ability of postjunctional -adrenoceptors to respond 
to exogenous NA is unaffected by adenine nucleotides, and provides 
further evidence that the reduction in amplitude of the second, 
noradrenergic component of the motor response to field stimulation is 
due to a reduction in neurally-released NA. It was not possible from 
such indirect experiments to determine whether or not the amount of ATP 
released by field stimulation was reduced in the presence of ATP, as
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the postjunctional receptors were less able to respond to exogenous 
ATP. However, it seems unlikely that activation of -purinoceptors 
would inhibit the release of NA, with no effect on ATP release. Thus,
the results obtained from these studies are consistent with the 
hypothesis that morphine and clonidine inhibit release of the NANC 
transmitter, leading to the removal of a negative feedback inhibition 
on NA release. This explanation would seem plausible if NA and the 
NANC transmitter are stored in separate vesicles. Differential 
regulation of release of co-existing neurotransmitters can be expected 
when the co-transmitters are stored in separate vesicles (Bartfai, 
1985). If either or both transmitters participate in presynaptic 
autoinhibition or mutual cross-regulation of co-transmitter release, 
then drugs that affect such mechanisms can be expected to have complex 
effects.
Since limited information can be obtained from experiments 
attempting to study the effects of drugs which act on presynaptic 
receptors by examining postsynaptic responses, this study investigated 
a second method of testing the proposed explanation of the actions of 
morphine and clonidine. The effects of these drugs were examined on 
the overflow of in vasa preincubated with (^H)-adenosine. This 
procedure results in the incorporation of label into (^H)-adenine 
nucleotides. There is evidence of release following transmural 
stimulation of guinea-pig vasa deferentia preincubated with (^ H)- 
adenosine (Westfall al., 1978). However, it still remains unclear 
whether ATP is released from presynaptic (Silinsky, 1973; Burnstock 
et al.. 1978) or postsynaptic (Kuchii at al*» 1975; Meunier, 1975) 
sites. The results obtained from such studies attempting to clarify 
the origin of ATP release are very contradictory. One approach that 
has been adopted in the vas deferens in an attempt to locate the source
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of ATP released by nerve stimulation, is to use a hypertonic bathing 
solution to prevent muscle contraction. Hypertonic solutions have 
been employed for electrophysiological investigations of smooth muscle 
(Tomita, 1970).
The results of this study, which examined overflow from vasa 
bathed in Krebs solution made hypertonic by the addition of sucrose 
(12.5$), failed to support or refute the hypothesis that morphine and 
clonidine inhibit the release of the NANC transmitter. The amounts of 
released into the bathing solution were small and were unaffected by 
either morphine or clonidine. This contraction-independent release of 
from (^H)-adenosine-treated tissues was insensitive to the action 
of TTX. Electrophysiological evidence indicates that depolarisation 
of nerve terminals may release transmitter, even in the presence of 
TTX, which blocks the inward Na+ current (Katz & Miledi, 1965). This 
may provide an explanation for the TTX-insensitive release evoked by 
field stimulation in this study. Alternatively, it may be due to the 
release of radioactivity as a result of direct electrical stimulation 
of the muscle.
Of importance to any discussion of transmitter release and 
function is the site of origin of the released putative transmitter 
and, in particular, whether release occurs from pre- or post-synaptic 
sites. This area is more confusing and contradictory than any other 
aspect of ATP metabolism. There is little doubt that ATP is released, 
together with catecholamines, from adrenal chromaffin cells (Geffen & 
Livett, 1971; Burnstock, 1976). However, in the case of neurones, 
the situation is far from clear. Evidence has been presented both for 
(Su at al., 1971) and against (Stjarne at &!•, 1970; Lagercrantz,
1976; Fredholm at &!•» 1981) a neuronal release of purines. Evidence 
concerning the vesicular distribution of ATP in the vas deferens is
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also conflicting, in contrast to NA, which is contained in the large 
and small dense-cored vesicles, first observed by Grillo and Palay 
(1962) and now characterised both morphologically (Geffen & Livett,
1971) and biochemically (Nelson & Molinoff, 1976). The distribution 
of dopamine-p-hydroxylase in the rat vas deferens implies that NA 
synthesis occurs in large dense-cored vesicles (Fried et. al., 1978).
All of the current evidence indicates that enzymically active dopamine-3- 
hydroxylase occurs primarily, if not exclusively, in large dense-cored 
vesicles (Fried et. 1978) implying that the large vesicles possess
a high capacity for NA synthesis. The newly-synthesised NA is present 
as a fast release pool which saturates rapidly, resulting in the 
overflow of NA to the cytoplasm. From there, NA is taken up and 
stored in the small vesicles (Fried £_£. al.., 1978; Klein & Lagercrantz, 
1982).
In contrast to NA distribution, about which there is general 
agreement across various pharmacological disciplines, the distribution 
of ATP remains inconclusive. Early studies showed a NA:ATP ratio of 
4:1 in noradrenergic vesicle preparations of splenic nerves and 1.3-3.7 
in preparations from vas deferens (Geffen & Livett, 1971), therefore,
NA was assumed to be stored with ATP in both small and large vesicles 
in the ratio of 4:1 (Geffen & Livett, 1971)> as in adrenal chromaffin 
granules (Winkler, 1976). This fitted in well with the hypothesis of 
catecholamine storage in a binding complex together with ATP.
However, these early findings were shown to be in error due to 
contamination (De Potter £t. al., 1970) and later studies with large 
vesicles free from mitochondrial contamination gave values of 7.5-12.1 
(Lagercrantz, 1976).
It is difficult to draw conclusions about the distribution of ATP 
in the vas deferens since, even in castrated preparations, there is
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muscular tissue present (Fried si.., 1978). There is evidence that 
small vesicles can accumulate (^H)-ATP (Geffen & Livett, 1971), 
although the amounts may be quite small (Lagercrantz & Stjarne, 1974).
The available morphological and biochemical evidence supports the 
hypothesis that both the large and the small vesicles release NA on 
nerve stimulation (Trifaro & Cubbedo, 1981). Under normal 
physiological conditions it is assumed that small vesicles are 
responsible for the primary release of NA from nerve terminals. Large 
vesicles, which contain approximately ten times more NA per vesicle 
than small vesicles (Fried e£ .aX., 1984), probably become more 
important during more intense stimulation, such as was used in this 
study.
The existence of a second NANC transmitter in the vas deferens has 
been shown, although its distribution and possible involvement in 
transmission remain to be clarified. Immunohistochemical studies have 
uncovered the presence of neuropeptide Y-like immunoreactivity (NPY-LI) 
in vasa of a variety of animals (Lundberg e£ al., 1982; 1983).
Neuropeptides appear to be stored only in large vesicles, as shown by 
electronmicroscopic and subcellular studies (Hokfelt et. nl., 1980; 
Fried, 1982) and, in the rat vas deferens, NPY has been suggested to be 
contained in large vesicles (Fried si ill.., 1984). NPY may potentiate 
the effects of NA and ATP in the mouse vas deferens, as exogenous NPY 
rapidly increased the contractions induced by NA and ATP (Stjarne 
et al.. 1986). Thus, the contractile response to nerve stimulation in 
this tissue may be due to the dynamic interplay of 3 transmitter 
substances with the relative importance of NPY increasing with greater 
frequencies of stimulation. This may provide an explanation for some 
of the experimental observations obtained in this study. A greater 
overflow of (^H)-NA was obtained with trains of 100 pulses at a
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frequency of 1 Hz than with trains of 100 pulses at a frequency of 
20 Hz. This occurred irrespective of whether the experiment commenced 
with the highest or the lowest frequency. It is possible that, at the 
higher frequencies of stimulation, complex feedback processes come into 
operation in order to "spare” the main transmitter from being depleted 
(Stjarne e£. 1986). It has been postulated that the importance of
NPY increases with increasing frequencies of stimulation (Lundberg 
&!•» 1986) and that NPY may have a dual role, firstly to "amplify" 
the effects of the main motor transmitters and, subsequently, to "turn 
off" the secretory activity, i.e. a transmitter sparing effect (Stjarne 
e£. si.., 1986). The parameters of stimulation used in this study may 
have been optimal for the release of NPY (in agreement with Lundberg 
et SJL•, 1986) and NPY released at a frequency of 20 Hz may have 
inhibited the release of NA. Since the overflow of NA obtained at a 
frequency of 1 Hz was significantly greater than at higher frequencies 
of stimulation, it may be that NA is being released at this frequency 
of stimulation primarily from small vesicles and the main regulation of 
release is through presynaptic c^-adrenoceptors. The addition of PBA 
produced approximately twice the overflow of (^H)-NA in comparison with 
controls. However, the addition of PBA to vasa stimulated at a 
frequency of 20 Hz produced a comparable increase in (^H)-NA to that 
obtained at the lower frequency, indicating that presynaptic cu,- 
adrenoceptors are equally involved in regulation at low and high 
frequencies of stimulation. Therefore, since the difference in the 
amount of transmitter released does not appear to be due to varying 
regulation through presynaptic a2-adrenoceptors, it is possible that 
NPY is involved in a "sparing effect", as has been postulated (Stjarne 
elsl., 1986).
68
This study showed that the amount of (^H)-NA released over the 
initial 3 stimulations in the absence of any drugs decreased and then 
levelled off. It is noteworthy that such a phenomenon has previously 
been reported in the guinea-pig vas deferens (Macrae, 1983). In a 
tissue such as the atria, where there is no evidence for co­
transmission, this reduction in overflow does not occur (Boyle, 
personal communication). It is possible that the stimulation 
parameters used in this study elicited transmitter release from all 
vesicular types and a complicated system of feedbacks came into 
operation with the ultimate outcome of preventing NA from being 
depleted. It is difficult to explain why there was a consistent 
reduction in (^H)-NA overflow over the first 3 stimulations unless this 
system, involving a fine balance among 3 transmitters, requires an 
adjustment period before NA release becomes constant. Such an 
explanation is weak and merely serves to illustrate why understanding 
of transmission in this tissue has remained elusive for so many years. 
It may be that in the interval between the first and fourth 
stimulations, the system attains an equilibrium whereby the ability of 
NPY to regulate the release of NA increases and then stays constant.
Experiments examining the effects of drugs on overflow from 
tissues preincubated with (^H)-adenosine or (^H)-NA may provide 
limited information. It is possible that incubation of tissues in a 
radioactive solution results in pools of transmitter being non- 
uniformly labelled. The magnitude of the effect on (^H)-NA overflow 
obtained with morphine and clonidine may be exaggerated and give a 
misleading impression of its importance due to the possible 
inadequacies of this technique in labelling all of the stores of 
transmitter equally. Because of the possible drawbacks of the 
overflow technique and the lack of information from experiments
69
designed to measure release of the putative transmitter ATP, another 
approach was adopted to examine further the unexpected results obtained 
with morphine and clonidine from experiments examining their effects on 
mechanical responses and on (^H)-NA overflow. The effects of NA and 
the putative transmitter ATP were compared to the effects of field 
stimulation in their ability to stimulate postsynaptic coupling 
mechanisms in the vas deferens. The possibility that morphine and 
clonidine act postsynaptically was examined, together with their 
proposed action of enhancing the field stimulation-induced release of 
NA.
Activation of smooth muscle by transmitters and drugs involves, at
p.
least in part, the release of intracellular calcium ([Ca ]^ ) from the 
sarcoplasmic reticulum. Until recently, the mechanism by which this 
occurred was unknown. A common observation is that all agonists which 
induce a phosphatidylinositol (PI) response evoke a cellular response 
that results in an elevation of [Ca2+]i). This observation led to 
the introduction of a hypothesis suggesting a causal relationship 
between phosphoinositide hydrolysis and Ca2+ mobilisation (Michell, 
1975). PI turnover is stimulated by adrenergic and cholinergic 
agonists in several tissues and this effect is mediated through 
a^-adrenoceptors and muscarinic cholinoceptors respectively (Carnessa 
de Scarnati & Lapetina, 1974; Lapetina at al,, 1976; Villalobos- 
Molina at al.., 1982; Fox at al., 1985). Many cellular processes such 
as contraction (Michell, 1975; Burgess et al., 1984) are regulated by 
Ca2+-mobilising receptors, which stimulate the hydrolysis of 
phosphatidylinositol 4,5-bisphosphate (PIP2), with the consequent 
generation of the two intracellular second messengers 
1,2-diacylglycerol (DG) and inositol 1,4,5-trisphosphate (IP3)
(Berridge & Irvine, 1984; Downes & Michell, 1985). IP3 diffuses into
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the cytosol to release Ca2+ from intracellular stores (Berridge & 
Irvine, 1984). DG can be phosphorylated by a kinase to phosphatidic 
acid (PA), and the levels of PA are increased when the PI cycle is 
activated. This provides a method of monitoring the turnover of PI.
This study investigated the effects of exogenous agonists on 
[32P]-PA formation in the vas deferens and compared their effects to 
those of field stimulation. The effects of morphine and clonidine 
were examined on this system in an attempt to confirm their unusual 
action in the vas deferens, revealed by experiments examining both 
mechanical responses and transmitter overflow. NA and electrical 
field stimulation increased the formation of [32P]-PA and these effects 
were antagonised by the -adrenoceptor antagonist prazosin. These 
results suggest that in the mouse vas deferens, as in other smooth 
muscle (Abdel-Latif, 1974; Lapetina et. &L., 1976; Campbell et al..
1985), inositol phospholipids are intimately involved in signal 
transduction of the response triggered by 0^ -adrenoceptor occupation. 
The field stimulation-induced enhancement of [32P]-PA formation was 
inhibited by TTX, indicating that it was neurally-mediated. The 
ability of prazosin to block the effects of field stimulation on 
[32P]-PA formation indicated that only the NA released by field 
stimulation had any effect on PI metabolism. If the NANC co- 
transmitter(s) had influenced the hydrolysis of PI, prazosin would have 
been unlikely to completely block the enhanced [32P]-PA formation 
resulting from field stimulation. Neither ATP nor its stable 
analogue, a,P-MeATP, affected [32P]-PA formation indicating that the 
field stimulation-induced NANC response mediated by ATP does not 
involve the hydrolysis of PI.
Morphine and clonidine had no effect on the basal levels of [32]- 
PA formation or the ability of NA to enhance the formation of [32P]-PA,
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indicating that these drugs do not act postsynaptically either to 
affect [3^P]-PA formation directly or to enhance the effects of NA on 
[32p-j_pA formation. However, both drugs potentiated the ability of 
electrical field stimulation to increase the formation of [^^P]-PA.
These results indicated that the site of action of morphine and clonidine 
is presynaptic, resulting in a potentiation of the release of NA.
These results confirmed the previous findings from studies employing 
more traditional pharmacological techniques and suggested that the 
complex actions of morphine and clonidine to increase both the 
adrenergic component of the biphasic motor response of the mouse vas 
deferens and the overflow of (^H)-NA are real effects and cannot be 
attributed to unexplained properties peculiar to a species or, 
alternatively, to a "presynaptic protecting effect", such as has been 
postulated to explain the similar effects of clonidine in the guinea- 
pig vas deferens (Stjarne, 1975a). This highlights the quandary faced 
by many pharmacologists when their experimental observations do not fit 
into accepted dogma. Do they simply ignore or dismiss their data?
It is interesting that the proposed alteration in the relative 
importance of the co-transmitters in the vas deferens, depending on the 
parameters of stimulation, has a parallel in the signal pathway 
utilising the second messengers generated from IP2. Release of Ca^+ 
from the endoplasmic reticulum by IP^ is only one branch of a 
bifurcating signal pathway. The other component is DG, which 
actives protein kinase C (Nishizuka, 1984). One very important aspect 
of this bifurcation is that the 2 branches often act synergistically 
with each other (Kaibuchi e£. al., 1983; Nishizuka, 1984) and both 
second messengers are often required to produce a maximal response.
Ca^+ ionophores have been used to bypass the actions of IP^ in 
elevating [Ca^+]^  levels. Phorbol esters, which mimic DG (Nishizuka,
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1984), have been shown to induce a slowly-developing tonic contraction 
of vascular smooth muscle (Banthuluri & Deth, 1984). When added 
together, phorbol esters and Ca^+ ionophores produced a sustained
contraction, thus in many cellular processes both IP^ and DG are
required to produce a maximum response.
In the vas deferens, it would seem that all the co-transmitters are 
intimately involved in the process of transmission. It may be that 
the vas responds to alterations in stimulation by shifting the emphasis 
from one neurotransmitter to another and triggering several different 
and rather complex feedback interactions in order to sustain 
transmission. Stimulation at high frequencies will produce a 
contraction which is the resultant effect of a small number of chemical
messengers, avoiding the sole utilisation of any one, with the
possibility of exhaustion.
It is interesting to speculate that the greater the number of co­
transmitters, the greater the number of potential feedback interactions 
to control the release of the "main" transmitter.
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Thyroxine-induced changes in sensitivity
Thyroid hormones are known to influence the sensitivity of 
sympathetically-innervated tissues to agonists (Gibson, 1981).
Whereas most studies investigating the effects of these hormones have 
examined their effects on postsynaptic receptor sensitivity, this study 
set out to determine whether or not chronic pretreatment affected 
the sensitivity of presynaptic receptors and if the changes in 
postsynaptic receptor sensitivity occurred as a result of presynaptic 
changes. administration raised the levels of free in the plasma
and produced changes in the responsiveness of the mouse vas deferens to 
drugs acting both pre- and post-synaptically. Chronic treatment with 
Tjj reduced the sensitivity of smooth muscle to NA and ACh. This 
subsensitivity was characterised by a reduction in the maximum response 
to NA with no shift in the position of the dose-response curve. In 
addition to a reduced maximum response to carbachol, there was a 
rightwards displacement of the dose-response curve for this agonist.
The subsensitivity to both NA and carbachol is one example of a 
widespread phenomenon in which the response to several agonists is 
impaired (Su ££. .§2,., 1976a; b). This phenomenon, described as 
heterologous desensitisation, occurs by more than one mechanism 
(Harden, 1983). Since the turnover of inositol phospholipids is 
stimulated by adrenergic and cholinergic agonists in several tissues 
(Carness de Scarnati & Lapetina, 1974; Lapetina et. al., 1976; Fox et. 
al.. 1985), it is possible that T^ pretreatment acts at a stage in this 
cycle, disrupting the second messenger pathway linking activation of 
muscarinic receptors and a^-adrenoceptors to a change in the 
responsiveness of the cell.
The results obtained from the field stimulated tissues indicated 
that Tjj pretreatment may also have influenced the sensitivity of
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presynaptic receptors, as there was a reduction in the maximum capacity 
of both morphine and clonidine to inhibit field stimulation-induced 
responses. The stimulation parameters used in this part of the study, 
that is, trains of 10 pulses at a frequency of 20 Hz, were most likely 
to have released the NANC transmitter(s), as no detectable overflow of 
(^H)-NA was obtained using these parameters of stimulation. In light 
of this evidence, it is interesting that clonidine could produce up to 
90% inhibition of the twitch responses, since clonidine’s accepted 
action as a prototype o^-adrenoceptor agonist, is not sufficient to 
explain this observation. Clonidine also appears to activate 
purinoceptors, blocking a presynaptic autoinhibitory mechanism 
(Katsuragi & Furakawa, 1985). However, the results obtained in this 
study would suggest that clonidine may, indeed, activate purinoceptors 
but in the capacity of an agonist and not as an antagonist as proposed 
by Katsuragi and Furakawa (1985). Clonidine may stimulate a 
presynaptic autoinhibitory mechanism leading to a reduction of ATP 
release. This mode of action of clonidine alone would be unlikely to 
produce a 90  ^ inhibition of field stimulation-induced twitch responses. 
Thus, clonidinefs ability to inhibit twitches in the vas may be the 
resultant effect of blocking a presynaptic P^-purinoceptor-mediated 
autoinhibition of ATP release together with blockade of a presynaptic 
o^-adrenoceptor-mediated modulation of ATP release. Although NA can 
not be detected at the stimulation parameters used in these studies, 
there may be a sufficient threshold concentration of neurally-released 
NA in the synaptic cleft to activate presynaptic o^-adrenoceptors and 
inhibit the release of ATP. Since T^ pretreatment produced a
significant subsensitivity to clonidine at all concentrations, but a
significant subsensitivity to morphine only at the highest
concentration, it is possible that the effect of T^ pretreatment was on
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the mechanisms activated by clonidine and the change in sensitivity of 
opiate receptors was secondary to this change. Both o^-adrenoceptors 
and opiate receptors, located on nerve terminals, may be linked to a 
common mechanism that inhibits transmitter release (McCulloch &
Pollock, 1985). It has been clearly established that presynaptic 
o^-adrenoceptors mediate inhibition of adenylate cyclase (Jacobs, 1985) 
and there is some evidence that opioids may also modulate the activity 
of this transduction mechanism (West & Miller, 1983). It has been 
suggested that presynaptic purinoceptors may also inhibit adenylate 
cyclase (Sneddon et 1984) and, therefore, any adaptation in this
common pathway may produce a subsensitivity to the effects of drugs 
acting presynaptically. Although it is possible that pretreatment 
merely had a "toxic" effect on nerve terminals, removing the inhibitory 
capacity of presynaptic receptors, this is an unlikely explanation of 
the results, since the ability of clonidine to inhibit responses was 
affected to a greater extent than morphine. A non-specific effect on 
nerve endings would have been more likely to affect the inhibitory 
capacity of both drugs similarly.
Results from experiments investigating the effects of pretreatment 
with a combination of Tj^ + 6-OHDA suggested that the changes in 
postsynaptic receptor sensitivity occurred as a result of changes 
presynaptically. If the observed subsensities both pre- and post- 
synaptically had occurred independently of each other, Tj^ pretreatment 
of denervated animals would have resulted in less of a supersensitivity 
than was obtained in animals treated with 6-OHDA alone. However, this 
was not the experimental observation that was obtained. Pretreatment 
with a combination of 6-OHDA + resulted in an even greater 
postsynaptic supersensitivity than occurred as a result of 6-OHDA 
pretreatment alone.
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Limited information can be obtained from studies where the 
recorder speed was running slowly and field stimulation released only 
the NANC transmitter. Studies monitoring the overflow of (^H)-NA 
revealed that in the absence of any drugs, there was an enhanced 
overflow of (^H)-NA, indicating that pretreatment inhibited the 
presynaptic mechanisms which normally regulate transmitter release. It 
is possible that these receptors became subsensitive because there was 
more NA in the vicinity of the receptors due to an impairment of the 
removal mechanisms for NA. This was tested by blocking MAO and the 
neuronal and extraneuronal uptake of NA. The results showed that T^  
pretreatment did not significantly alter these processes. This study 
provided evidence that T^ pretreatment produced a subsensitivity of 
presynaptic o^-adrenoceptors. PBA, which blocks the uptake processes 
and both pre- and post-synaptic -adrenoceptors, produced less of an 
enhancement of (^H)-NA overflow in tissues from treated animals than 
from controls. It is possible that PBA may also block presynaptic P^- 
purinoceptors and, in T^ pretreated animals, the reduced overflow of 
(^H)-NA resulted from a combined subsensitivity of both o,- 
adrenoceptors and P^-purinoceptors on nerve endings.
Morphine and clonidine did not produce a significant enhancement 
of (^H)-NA overflow in vasa from T^ pretreated animals unlike their 
effect in vasa from control animals. This observation is consistent 
with the explanation that T^  pretreatment resulted in a change in the 
sensitivity of presynaptic receptors, inhibiting their ability to 
regulate transmitter release. This observation further supports the 
experimental results obtained with morphine and clonidine throughout 
the study since, if these drugs normally inhibit a presynaptic 
inhibitory regulatory mechanism on transmitter release, leading to the 
enhanced release of NA, preventing this feedback from operating
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efficiently by pretreating animals with will prevent morphine and 
clonidine from enhancing NA release.
In conclusion, the effects of morphine and clonidine have 
confirmed the complexity of transmission in the vas deferens, first 
suggested by Ambache and Zar (1951). The evidence obtained in this 
study is consistent with the hypothesis that the vas possesses more 
than one transmitter. Drugs such as morphine and clonidine may 
preferentially inhibit the release of at least one of the co­
transmitters which normally regulates the release of NA. Altering the 
hormonal environment of this tissue produced results consistent with 
this proposed explanation. This study provided answers for some of 
the unresolved questions in the vas, such as whether or not the 
transmitters are contained in a single nerve or in separate nerves, and 
if chronic T^ pretreatment altered the sensitivity of presynaptic 
receptors. However, other questions have been raised in the course of 
the study:
(1) What is the transmitter responsible for the 'spike1 component
of the mechanical response? Is it ATP?
(2) If it is, indeed, ATP, what is the vesicular distribution of
this putative transmitter?
(3) What is the relative importance of NPY in the vas deferens?
(4) How could drugs preferentially inhibit release of one trans­
mitter at high frequencies of stimulation, even if the
transmitters are stored in separate vesicles?
Of interest in this study was the ability of chronic T^- 
pretreatment to abolish the effect of drugs on NA release. This may 
provide an important means of altering the ability of drugs to act 
presynaptically to interfere with complex feedback regulations on
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transmitter release and provides further evidence that chronic hormone 
treatment produces multiple effects throughout the body, both pre- and 
post-synaptically.
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